

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 NOV 21 CAS patent coverage to include exemplified prophetic
substances identified in English-, French-, German-,
and Japanese-language basic patents from 2004-present
NEWS 3 NOV 26 MARPAT enhanced with FSORT command
NEWS 4 NOV 26 CHEMSAFE now available on STN Easy
NEWS 5 NOV 26 Two new SET commands increase convenience of STN
searching
NEWS 6 DEC 01 ChemPort single article sales feature unavailable
NEWS 7 DEC 12 GBFULL now offers single source for full-text
coverage of complete UK patent families
NEWS 8 DEC 17 Fifty-one pharmaceutical ingredients added to PS
NEWS 9 JAN 06 The retention policy for unread STNmail messages
will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
Classification Data
NEWS 11 FEB 02 Simultaneous left and right truncation (SLART) added
for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 12 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13 FEB 06 Patent sequence location (PSL) data added to USGENE
NEWS 14 FEB 10 COMPENDEX reloaded and enhanced
NEWS 15 FEB 11 WTEXTILES reloaded and enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:07:39 ON 12 FEB 2009

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 09:07:50 ON 12 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 FEB 2009 HIGHEST RN 1104680-36-5
DICTIONARY FILE UPDATES: 11 FEB 2009 HIGHEST RN 1104680-36-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10596500.str



chain nodes :

10 18 19 22

ring nodes :

1 2 3 4 5 6 7 8 9 11 12 13 14 15 16

chain bonds :

8-18 9-10 10-11 18-19 18-22

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 11-12 11-16 12-13 13-14 14-15
15-16

exact/norm bonds :

2-7 3-9 7-8 8-9 8-18 9-10 18-19 18-22

exact bonds :

10-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
isolated ring systems :
containing 1 : 11 :

G1: Ak, H

G2: Cb, Ak

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 18:CLASS 19:CLASS 22:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



G1 Ak, H

G2 Cb, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 09:08:10 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 173 TO ITERATE

100.0% PROCESSED 173 ITERATIONS

30 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 2671 TO 4249

PROJECTED ANSWERS: 272 TO 928

L2 30 SEA SSS SAM L1

=> s 11 sss full

FULL SEARCH INITIATED 09:08:15 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3704 TO ITERATE


100.0% PROCESSED 3704 ITERATIONS
SEARCH TIME: 00.00.01

470 ANSWERS

L3 470 SEA SSS FUL L1

=> d scan


L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Pyridinol, 2-[[5,7-dimethyl-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-
1H-benzimidazol-1-yl]methyl]-6-methyl-
MF C24 H34 N6 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):40


L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Pyridinol, 6-methyl-2-[[2-[[2-(3-methylphenyl)ethyl]amino]-1H-
benzimidazol-1-yl]methyl]-
MF C23 H24 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Acetamide, N-[6-formyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-

1H-benzimidazol-2-yl]-
MF C24 H22 N4 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[2-(4-morpholinyl)ethyl]amino]-
MF C20 H25 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1H-Benzimidazol-2-amine, 6-(chloromethyl)-1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-N-[3-(4-morpholinyl)propyl]-
MF C23 H30 Cl N5 O2
CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN Carbamic acid, [2-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI)
 MF C37 H51 N7 O4





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(tetrahydro-1,4-oxazepin-4(5H)-yl)propyl]amino]-
 MF C23 H31 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-
 MF C21 H27 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 1H-Benzimidazole-6-methanamine, N-(2,5-dimethylphenyl)-1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-
 MF C30 H38 N6 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 1H-Benzimidazole-6-methanamine, 1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-
 N-[2-[2-(4-morpholinyl)ethyl]phenyl]-2-[[3-(4-morpholinyl)propyl]amino]-
 MF C35 H47 N7 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-
 [[3-(4-thiomorpholinyl)propyl]amino]-
 MF C22 H29 N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 3-Pyridinol, 2-[[6-[(2,3-dihydro-6-methyl-1H-indol-1-yl)methyl]-2-[[3-(4-
 morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
 MF C31 H38 N6 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)-2-pyrimidinylamino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
 MF C28 H36 N8 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN Propanamide, 3-[(3-ethynylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-
 MF C33 H39 N7 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN Butanamide, 4-[(4-cyanophenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-
 MF C33 H40 N8 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN Butanamide, 4-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-
 pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-
 yl]methyl]amino]-N-methyl-
 MF C35 H47 N7 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)(2-hydroxyethyl)amino]methyl]-2-
 [[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
 MF C32 H42 N6 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 3-Pyridinol, 2-[[6-[[[2-[(2-hydroxyethyl)amino]-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
 MF C31 H41 N7 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 3-Pyridinol, 2-[[6-[[[2-(4-hydroxybutyl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
 MF C33 H44 N6 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 1H-Benzimidazole-6-carboxaldehyde,
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(1-
 piperidinyl)propyl]amino]-
 MF C23 H29 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 3-Pyridinol, 2-[[5-[[[(3,5-dimethylphenyl)amino]methyl]-2-[[3-(1-
 piperidinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
 MF C31 H40 N6 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 3-Pyridinol, 2-[[2-[(3-hydroxypropyl)amino]-1H-benzimidazol-1-yl]methyl]-6-
 methyl-
 MF C17 H20 N4 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 3-Pyridinol, 2-[[2-[[4-(2-aminoethyl)phenyl]amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl-
 MF C24 H27 N5 O
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN Benzamide, 4-fluoro-N-[1-[2-(2-pyridinyl)ethyl]-5-(trifluoromethyl)-1H-benzimidazol-2-yl]-
 MF C22 H16 F4 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN INDEX NAME NOT YET ASSIGNED
 MF C33 H32 N6 O3


Cc1cc(C)cc(NCCc2ccc3c(c2)nc(NC(=O)CCCC)c3NCCc4c(O)c(C)nc4)c1

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

CC1=CC=C(C2=CC(=C(C=C2)N(C(=N2)N(C(=N2)C3=CC(=C(C=C3)O)C)C)C)C)C1


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN Acetamide, N-[6-[[[(2,5-dimethylphenyl)amino]methyl]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]-
 MF C25 H27 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 1H-Imidazo[4,5-c]pyridinium, 1-cyclopropyl-2,3-dihydro-5-[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-5-yl]methyl]-2-oxo-, inner salt
 MF C30 H34 N8 O3




L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 3-Pyridinol, 2-[[6-(chloromethyl)-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
 MF C22 H28 Cl N5 O2
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1H-Benzimidazole-6-methanol, 1-[(6-bromo-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-
MF C21 H26 Br N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1H-Benzimidazole-5-methanol, 2-[[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]propyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-, rel-
MF C24 H33 N5 O3

Relative stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN Benzenepropanol, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-5-yl]methyl]amino]-4-methyl-
 MF C33 H44 N6 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN Benzamide, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-
 MF C30 H37 N7 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN Benzeneethanol, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-
 MF C31 H40 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 1H-Benzimidazole-6-methanol, 2-[[3-[(2R,6R)-2,6-dimethyl-4-morpholinyl]propyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-, rel-
 MF C24 H33 N5 O3

Relative stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 1-Propanesulfonamide, 3-[[4-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-3,5-dimethylphenyl]amino]-, hydrochloride (1:?)
 MF C33 H45 N7 O4 S . x Cl H




● x HCl

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)(2-methyl-5-(1-methylethyl)phenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
 MF C34 H46 N6 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)(2-methylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
 MF C31 H40 N6 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 1-Butanesulfonamide, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl](3-methylphenyl)amino]-
 MF C33 H45 N7 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 470 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN β -Alanine, N-(3,5-dimethylphenyl)-N-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-, ethyl ester
 MF C35 H46 N6 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil cap

COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 186.84 | 187.06 |

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 09:09:36 ON 12 FEB 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Feb 2009 VOL 150 ISS 7
FILE LAST UPDATED: 11 Feb 2009 (20090211/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 09:07:39 ON 12 FEB 2009)

FILE 'REGISTRY' ENTERED AT 09:07:50 ON 12 FEB 2009

L1 STRUCTURE UPLOADED
L2 30 S L1
L3 470 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 09:09:36 ON 12 FEB 2009

=> s 13

L4 16 L3

=> s 13 and (pry<2004)

16 L3
4266527 PRY<2004
L5 7 L3 AND (PRY<2004)

=> s 13

L6 16 L3

=> d 1-16 ibib abs hitstr

L6 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1508519 CAPLUS

DOCUMENT NUMBER: 150:56153

TITLE: Benzimidazole derivatives and related compounds for inhibiting KSP kinesin activity and their preparation and use in the treatment of KSP-associated diseases
INVENTOR(S): Shipps, Gerald W., Jr.; Ma, Yao; Lahue, Brian Robert; Seghezzi, Wolfgang; Herbst, Ronald; Chuang, Cheng-Chi; Annis, D. Allen; Kirtley, Matthew

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 319pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|------|-----------------|------|
|------------|------|------|-----------------|------|

| | | | | |
|---------------|--|----------|----------------|----------|
| ----- | ----- | ----- | ----- | ----- |
| WO 2008153701 | A1 | 20081218 | WO 2008-US6472 | 20080521 |
| W: | AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |

PRIORITY APPLN. INFO.:



US 2007-939963P

P 20070524

OTHER SOURCE(S):

MARPAT 150:56153

GI




AB The invention provides compds. of formula I as KSP kinesin inhibitors. The invention also provides compns. comprising these compds. that are useful for treating cellular proliferative diseases or disorders associated with KSP kinesin activity and for inhibiting KSP kinesin activity. Compds. of formula I wherein R is H, (halo)alkyl, CN, halo, SH and derivs., etc.; R1 is alkyl, heterocyclyl, aroyl, NH2 and derivs., etc.; R2 and R3 are independently H, alkyl and (un)substituted methylene; R4 is alkyl, (un)substituted cycloalkyl, (un)substituted heterocyclyl, and (un)substituted (hetero)aryl; and pharmaceutically acceptable salts, solvates and esters thereof, are claimed. Example compound II was prepared by a general solid phase procedure (procedure given). All the invention compds. were evaluated for their KSP kinesin inhibitory activity (some data given).


IT 1092830-87-9P 1092830-97-1P 1092831-10-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of benzimidazole derivs. and related compds. as KSP inhibitors useful in treatment of KSP-associated diseases)

RN 1092830-87-9 CAPLUS



CN 1H-Benzimidazole-5-carboxamide, 2-[[4-(methylsulfonyl)phenyl]amino]-1-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 1092830-97-1 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 2-[[4-(aminosulfonyl)phenyl]amino]-1-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 1092831-10-1 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 2-[(4-methoxyphenyl)amino]-1-[[3-(trifluoromethyl)-2-pyridinyl]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:159875 CAPLUS

DOCUMENT NUMBER: 148:299037

TITLE: Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate. 2. Discovery of a Morpholinopropylaminobenzimidazole Derivative (TMC353121)

AUTHOR(S): Bonfanti, Jean-Francois; Meyer, Christophe; Doublet, Frederic; Fortin, Jerome; Muller, Philippe; Queguiner, Laurence; Gevers, Tom; Janssens, Peggy; Szel, Heidi;

Willebrords, Rudy; Timmerman, Philip; Wuyts, Koen; van Remoortere, Pieter; Janssens, Frans; Wigerinck, Piet; Andries, Koen

CORPORATE SOURCE: Medicinal Chemistry Department, Johnson and Johnson Pharmaceutical Research and Development, Val de Reuil, F-27106, Fr.

SOURCE: Journal of Medicinal Chemistry (2008), 51(4), 875-896
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 148:299037

AB A preceding paper reported the optimization of the pharmacokinetic profile of substituted benzimidazoles by reducing their tissue retention. However, the modifications that were necessary to achieve this goal also led to a significant drop in anti-RSV activity. This paper describes a mol. modeling study followed by a lead optimization program that led to the recovery of the initial potent antiviral activity and the selection of TMC353121 as a clin. candidate.

IT 857066-90-1P, 2-[[6-[[[2-(3-Hydroxypropyl)-5-methylphenyl]amino]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted benzimidazole derivs. as respiratory syncytial virus fusion inhibitors)

RN 857066-90-1 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(3-hydroxypropyl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
(CA INDEX NAME)




IT 857035-10-0P, 2-[[6-[(3,5-Dimethylphenylamino)methyl]-2-[[3-(4-methylpiperazin-1-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857035-11-1P, 3-[[6-[(3,5-Dimethylphenylamino)methyl]-1-[(3-hydroxy-6-methylpyridin-2-yl)methyl]-1H-benzimidazol-2-yl]amino]propane-1,2-diol 857035-20-2P, 2-[[2-[[2-(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl]amino]-6-[(3,5-dimethylphenylamino)methyl]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857035-23-5P, 2-[[6-[(3,5-Dimethylphenylamino)methyl]-2-phenethylaminobenzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857066-95-6P, 2-[[6-[[[2-(3-Hydroxypropyl)phenyl]amino]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857067-08-4P, 2-[[6-[[[2-(2-Hydroxyethyl)phenyl]amino]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857067-09-5P, 2-[[6-[(3,5-Dimethylphenylamino)methyl]-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857067-14-2P, 6-Methyl-2-[[2-[[3-(morpholin-4-yl)propyl]amino]-6-[(m-tolylamino)methyl]benzimidazol-1-yl]methyl]pyridin-

3-ol 857067-44-8P, 2-[[6-[[[(3,5-Dimethylphenyl)(2-hydroxyethyl)amino]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857067-45-9P 857067-72-2P, 2-[[6-[[[(2-Hydroxyethyl)-m-tolylamino]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857067-83-5P, 2-[[6-[[[(2-Hydroxyethyl)(phenyl)amino]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 1009646-66-5P, 2-[[2-[Butylamino]-6-[(3,5-dimethylphenylamino)methyl]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted benzimidazole derivs. as respiratory syncytial virus fusion inhibitors)


RN 857035-10-0 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857035-11-1 CAPLUS

CN 1,2-Propanediol, 3-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 857035-20-2 CAPLUS


CN 3-Pyridinol, 2-[[2-[[[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-6-[[[(3,5-dimethylphenyl)amino]methyl]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857035-23-5 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-2-[(2-phenylethyl)amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857066-95-6 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[2-(3-hydroxypropyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857067-08-4 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-09-5 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-14-2 CAPLUS

CN 3-Pyridinol, 6-methyl-2-[[6-[[3-(3-methylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 857067-44-8 CAPLUS

CN 3-Pyridinol, 2-[[6-[[3-(3,5-dimethylphenyl)(2-hydroxyethyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-45-9 CAPLUS


CN Butanamide, 4-[[3-(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-72-2 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)(3-methylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857067-83-5 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)phenylamino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 1009646-66-5 CAPLUS
 CN 3-Pyridinol, 2-[[2-(butylamino)-6-[[[(3,5-dimethylphenyl)amino]methyl]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




IT 857035-14-4P, 2-[[6-Hydroxymethyl-2-[[3-(4-methylpiperazin-1-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol
 857035-19-9P, 2-[[5-Hydroxymethyl-2-[[3-(4-methylpiperazin-1-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol
 857035-24-6P, 2-[[6-Hydroxymethyl-2-phenethylaminobenzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857067-38-0P,
 2-[[6-Hydroxymethyl-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857067-39-1P,
 2-[[5-Hydroxymethyl-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 857070-63-4P,
 3-[[3-Hydroxy-6-methylpyridin-2-yl]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]-3H-benzimidazole-5-carboxylic acid Ethyl Ester
 857070-64-5P, 1-[[3-Hydroxy-6-methylpyridin-2-yl]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]-1H-benzimidazole-5-carboxylic acid Ethyl Ester 857070-65-6P, 3-[[3-Hydroxy-6-methylpyridin-2-yl]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]-3H-benzimidazole-5-carboxaldehyde
 857070-68-9P 1009646-51-8P,
 3-[[3-Hydroxy-6-methylpyridin-2-yl]methyl]-2-[[3-(4-methylpiperazin-1-yl)propyl]amino]-3H-benzimidazole-5-carboxylic acid Ethyl Ester
 1009646-52-9P, 1-[[3-Hydroxy-6-methylpyridin-2-yl]methyl]-2-[[3-(4-methylpiperazin-1-yl)propyl]amino]-1H-benzimidazole-5-carboxylic acid Ethyl Ester 1009646-53-0P,
 3-[[3-Hydroxy-6-methylpyridin-2-yl]methyl]-2-[[3-(4-methylpiperazin-1-yl)propyl]amino]-3H-benzimidazole-5-carboxaldehyde 1009646-56-3P
 , 2-[[2-[[2,2-Dimethyl-[1,3]dioxolan-4-yl]methyl]amino]-3-[[3-hydroxy-6-methylpyridin-2-yl]methyl]-3H-benzimidazole-5-carboxylic acid Ethyl Ester
 1009646-57-4P, 2-[[2-[[2,2-Dimethyl-[1,3]dioxolan-4-yl]methyl]amino]-1-[[3-hydroxy-6-methylpyridin-2-yl]methyl]-1H-benzimidazole-5-carboxylic acid Ethyl Ester 1009646-58-5P,
 2-[[2-[[2,2-Dimethyl-[1,3]dioxolan-4-yl]methyl]amino]-6-hydroxymethylbenzimidazol-1-yl]methyl]-6-methylpyridin-3-ol
 1009646-59-6P, 2-[[2-[[2,2-Dimethyl-[1,3]dioxolan-4-yl]methyl]amino]-5-hydroxymethylbenzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 1009646-60-9P, 2-[[2-[[2,2-Dimethyl-[1,3]dioxolan-4-yl]methyl]amino]-3-[[3-hydroxy-6-methylpyridin-2-yl]methyl]-3H-benzimidazole-5-carboxaldehyde 1009646-62-1P,
 2-Butylamino-3-[[3-hydroxy-6-methylpyridin-2-yl]methyl]-3H-benzimidazole-5-carboxylic Acid Ethyl Ester 1009646-63-2P,
 2-Butylamino-1-[[3-hydroxy-6-methylpyridin-2-yl]methyl]-1H-benzimidazole-5-carboxylic Acid Ethyl Ester 1009646-64-3P,
 2-[[2-[[Butylamino]-6-hydroxymethylbenzimidazol-1-yl]methyl]-6-methylpyridin-3-ol 1009646-65-4P,
 2-Butylamino-3-[[3-hydroxy-6-methylpyridin-2-yl]methyl]-3H-benzimidazole-5-carboxaldehyde 1009646-68-7P,
 3-[[3-Hydroxy-6-methylpyridin-2-yl]methyl]-2-phenethylamino-3H-benzimidazole-5-carboxylic Acid Ethyl Ester 1009646-69-8P,
 1-[[3-Hydroxy-6-methylpyridin-2-yl]methyl]-2-phenethylamino-1H-benzimidazole-5-carboxylic acid Ethyl Ester 1009646-70-1P,
 3-[[3-Hydroxy-6-methylpyridin-2-yl]methyl]-2-phenethylamino-3H-benzimidazole-5-carboxaldehyde
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of substituted benzimidazole derivs. as respiratory syncytial virus fusion inhibitors)


RN 857035-14-4 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]- (CA INDEX NAME)




RN 857035-19-9 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]- (CA INDEX NAME)




RN 857035-24-6 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[(2-phenylethyl)amino]- (CA INDEX NAME)




RN 857067-38-0 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857067-39-1 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857070-63-4 CAPLUS

CN 1H-Benzimidazole-6-carboxylic acid, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-, ethyl ester (CA INDEX NAME)




RN 857070-64-5 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-, ethyl ester (CA INDEX NAME)



RN 857070-65-6 CAPLUS
 CN 1H-Benzimidazole-6-carboxaldehyde,
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857070-68-9 CAPLUS
 CN 3-Pyridinol, 2-[[6-(chloromethyl)-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-, hydrochloride (1:4) (CA INDEX NAME)




● 4 HCl


RN 1009646-51-8 CAPLUS
 CN 1H-Benzimidazole-6-carboxylic acid,
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1009646-52-9 CAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid,
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1009646-53-0 CAPLUS
 CN 1H-Benzimidazole-6-carboxaldehyde,
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-methyl-1-
 piperazinyl)propyl]amino]- (CA INDEX NAME)




RN 1009646-56-3 CAPLUS
 CN 1H-Benzimidazole-6-carboxylic acid,
 2-[[[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-1-[(3-hydroxy-6-methyl-2-
 pyridinyl)methyl]-, ethyl ester (CA INDEX NAME)




RN 1009646-57-4 CAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid,
 2-[[[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-1-[(3-hydroxy-6-methyl-2-
 pyridinyl)methyl]-, ethyl ester (CA INDEX NAME)




RN 1009646-58-5 CAPLUS
 CN 1H-Benzimidazole-6-methanol, 2-[[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 1009646-59-6 CAPLUS
 CN 1H-Benzimidazole-5-methanol, 2-[[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 1009646-60-9 CAPLUS
 CN 1H-Benzimidazole-6-carboxaldehyde, 2-[[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 1009646-62-1 CAPLUS
 CN 1H-Benzimidazole-6-carboxylic acid,
 2-(butylamino)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-, ethyl ester
 (CA INDEX NAME)



RN 1009646-63-2 CAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid,
 2-(butylamino)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-, ethyl ester
 (CA INDEX NAME)




RN 1009646-64-3 CAPLUS
 CN 1H-Benzimidazole-6-methanol, 2-(butylamino)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 1009646-65-4 CAPLUS
 CN 1H-Benzimidazole-6-carboxaldehyde,
 2-(butylamino)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)

NAME)




RN 1009646-68-7 CAPLUS

CN 1H-Benzimidazole-6-carboxylic acid,
1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[(2-phenylethyl)amino]-,
ethyl ester (CA INDEX NAME)




RN 1009646-69-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid,
1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[(2-phenylethyl)amino]-,
ethyl ester (CA INDEX NAME)



RN 1009646-70-1 CAPLUS

CN 1H-Benzimidazole-6-carboxaldehyde,
1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[(2-phenylethyl)amino]- (CA
INDEX NAME)




REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN


ACCESSION NUMBER: 2007:954101 CAPLUS

DOCUMENT NUMBER: 147:377573
 TITLE: Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate. Improving the Pharmacokinetic Profile Using the Structure-Property Relationship
 AUTHOR(S): Bonfanti, Jean-Francois; Doublet, Frederic; Fortin, Jerome; Lacrampe, Jean; Guillemont, Jerome; Muller, Philippe; Queguiner, Laurence; Arnoult, Eric; Gevers, Tom; Janssens, Peggy; Szel, Heidi; Willebrords, Rudy; Timmerman, Philip; Wuyts, Koen; Janssens, Frans; Sommen, Cois; Wigerinck, Piet; Andries, Koen
 CORPORATE SOURCE: Medicinal Chemistry Department, Johnson & Johnson Pharmaceutical Research and Development, Val de Reuil, F-27106, Fr.
 SOURCE: Journal of Medicinal Chemistry (2007), 50(19), 4572-4584
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 147:377573
 AB The authors previously reported the discovery of substituted benzimidazole fusion inhibitors with nanomolar activity against respiratory syncytial virus. A lead compound of the series was selected for preclin. evaluation. This drug candidate, JNJ-2408068 (formerly R170591, 1), showed long tissue retention times in several species (rat, dog, and monkey), creating cause for concern. The authors herein describe the optimization program to develop compds. with improved properties in terms of tissue retention. The authors have identified the aminoethyl-piperidine moiety as being responsible for the long tissue retention time of 1. The authors have investigated the replacement or the modification of this group, and suggest that the pKa of this part of the mols. influences both the antiviral activity and the pharmacokinetic profile. The authors were able to identify new respiratory syncytial virus inhibitors with shorter half-lives in lung tissue.
 IT 856894-98-9P 856894-99-0P 857068-40-7P 950483-51-9P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (selection of a respiratory syncytial virus fusion inhibitor clin. candidate through improving the pharmacokinetic profile using the structure-property relationship)
 RN 856894-98-9 CAPLUS
 CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856894-99-0 CAPLUS
 CN 1,2-Propanediol, 3-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4,6-

dimethyl-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 857068-40-7 CAPLUS

CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 950483-51-9 CAPLUS

CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[[3-(methylamino)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




IT 950483-30-4

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(selection of a respiratory syncytial virus fusion inhibitor clin. candidate through improving the pharmacokinetic profile using the structure-property relationship)

RN 950483-30-4 CAPLUS

CN 3-Pyridinol, 2-[[2-[[3-(aminopropyl)amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




IT 856895-02-8P 856895-13-1P 950483-53-1P
950483-55-3P 950483-57-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(selection of a respiratory syncytial virus fusion inhibitor clin. candidate through improving the pharmacokinetic profile using the structure-property relationship)


RN 856895-02-8 CAPLUS

CN 3-Pyridinol, 2-[[2-[(3-hydroxypropyl)amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-13-1 CAPLUS

CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[(2-phenylethyl)amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 950483-53-1 CAPLUS


CN Acetamide, N-[2-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4,6-dimethyl-1H-benzimidazol-2-yl]amino]ethyl]- (CA INDEX NAME)




RN 950483-55-3 CAPLUS
 CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[[2-(phenylamino)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 950483-57-5 CAPLUS
 CN 3-Pyridinol, 2-[[2-(butylamino)-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




IT 856895-07-3P 856895-15-3P 856895-41-5P
 950483-42-8P 950483-44-0P 950483-46-2P
 950483-48-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (selection of a respiratory syncytial virus fusion inhibitor clin. candidate through improving the pharmacokinetic profile using the structure-property relationship)
 RN 856895-07-3 CAPLUS
 CN β -Alanine, N-[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4,6-dimethyl-1H-benzimidazol-2-yl]-, ethyl ester (CA INDEX NAME)




RN 856895-15-3 CAPLUS

CN 3-Pyridinol, 2-[[2-[[[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-41-5 CAPLUS

CN 1H-Benzimidazol-2-amine, N-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,6-dimethyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]- (CA INDEX NAME)




RN 950483-42-8 CAPLUS

CN 1H-Benzimidazol-2-amine, 4,6-dimethyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 950483-44-0 CAPLUS

CN 1,3-Propanediamine, N1-[4,6-dimethyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]-N3-methyl- (CA INDEX NAME)




RN 950483-46-2 CAPLUS

CN Acetamide, N-[2-[4,6-dimethyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]amino]ethyl- (CA INDEX NAME)



RN 950483-48-4 CAPLUS

CN 1,2-Ethanediamine, N1-[4,6-dimethyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]-N2-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2006:1356990 CAPLUS
 DOCUMENT NUMBER: 146:100696
 TITLE: Preparation of 1-[(2-amino-3-(substituted alkyl)-3H-benzimidazolyl)methyl]-3-substituted-1,3-dihydro-benzimidazol-2-ones with activity on respiratory syncytial virus (RSV)
 INVENTOR(S): Bonfanti, Jean-Francois; Muller, Philippe; Fortin, Jerome Michel Claude; Doublet, Frederic Marc Maurice
 PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd, Ire.
 SOURCE: PCT Int. Appl., 52pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|--|----------|------------------|------------|
| WO 2006136561 | A1 | 20061228 | WO 2006-EP63365 | 20060620 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| AU 2006260969 | A1 | 20061228 | AU 2006-260969 | 20060620 |
| CA 2612263 | A1 | 20061228 | CA 2006-2612263 | 20060620 |
| EP 1896473 | A1 | 20080312 | EP 2006-763808 | 20060620 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| JP 2008546738 | T | 20081225 | JP 2008-517487 | 20060620 |
| IN 2007DN09456 | A | 20080620 | IN 2007-DN9456 | 20071207 |
| MX 200716537 | A | 20080306 | MX 2007-16537 | 20071218 |
| CN 101203517 | A | 20080618 | CN 2006-80021972 | 20071219 |
| PRIORITY APPLN. INFO.: | | | EP 2005-76438 | A 20050620 |
| | | | WO 2006-EP63365 | W 20060620 |
| OTHER SOURCE(S): | CASREACT 146:100696; MARPAT 146:100696 | | | |
| GI | | | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [R = II or III; Q = H or alkyl optionally substituted with a heterocycle or Q = alkyl substituted with both a radical -OR4 and a heterocycle; Alk = alkanediyl; X = O or S; a1:a2a3:a4 = N:CHCH:CH, CH:NCH:CH, CH:CHN:CH or CH:CHCH:N; R1 = Ar or a heterocycle; R2 = H, (un)substituted alkyl, cycloalkyl; R3 = H, alkyl, cyano, aminocarbonyl, polyhaloalkyl, alkenyl or alkynyl; R4 = H or alkyl; Ar = (un)substituted Ph; and their salts], useful as inhibitors of RSV replication, were prepared E.g., a multi-step synthesis of IV, starting from V, was given.
 Exemplified compds. I were screened in vitro for their activity against respiratory syncytial virus (pEC50 values were provided). Pharmaceutical compns. containing compds. I and processes for preparing compds. I were

disclosed.


IT 918151-94-7P 918151-95-8P 918151-96-9P
918151-97-0P 918151-98-1P 918152-00-8P
918152-01-9P 918152-03-1P 918152-04-2P
918152-05-3P 918152-06-4P 918152-07-5P
918152-08-6P 918152-10-0P 918152-11-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1-[(2-amino-3-(substituted alkyl)-3H-benzimidazolyl)methyl]-3-substituted-1,3-dihydro-benzimidazol-2-ones with activity on respiratory syncytial virus)


RN 918151-94-7 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 1-cyclopropyl-2,3-dihydro-5-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-, inner salt (CA INDEX NAME)




RN 918151-95-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 1-cyclopropyl-2,3-dihydro-5-[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-, inner salt (CA INDEX NAME)




RN 918151-96-9 CAPLUS

CN 2H-Imidazo[4,5-c]pyridinium, 1,3-dihydro-1-(2-hydroxyethyl)-5-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-, inner salt (CA INDEX NAME)



RN 918151-97-0 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridinium, 2,3-dihydro-5-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-1-[2-(phenylmethoxy)ethyl]-, inner salt (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


—CH₂—Ph

RN 918151-98-1 CAPLUS
 CN 1H-Benzimidazole-5-carbonitrile, 1-cyclopropyl-2,3-dihydro-3-[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo- (CA INDEX NAME)




RN 918152-00-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 2,3-dihydro-5-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-1-(3-phenylpropyl)-, inner salt (CA INDEX NAME)



RN 918152-01-9 CAPLUS


CN 1H-Imidazo[4,5-c]pyridinium, 2,3-dihydro-5-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-1-(2-phenylethyl)-, inner salt, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 918152-03-1 CAPLUS

CN 2H-Benzimidazol-2-one, 1-cyclopropyl-1,3-dihydro-3-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]- (CA INDEX NAME)




RN 918152-04-2 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-3-(2-phenylethyl)- (CA INDEX NAME)




RN 918152-05-3 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 1-cyclopropyl-2,3-dihydro-5-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[2-(4-morpholinyl)ethyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-, inner salt (CA INDEX NAME)




RN 918152-06-4 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 1-cyclopropyl-2,3-dihydro-5-[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[2-(4-morpholinyl)ethyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-, inner salt (CA INDEX NAME)





RN 918152-07-5 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridinium, 2,3-dihydro-5-[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-1-(2-phenylethyl)-, inner salt (CA INDEX NAME)



RN 918152-08-6 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridinium, 1-[2-(4-fluorophenyl)ethyl]-2,3-dihydro-5-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-oxo-, inner salt (CA INDEX NAME)


PAGE 1-A






RN 918152-10-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridinium, 1-cyclopropyl-2,3-dihydro-5-[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-5-yl]methyl]-2-oxo-, inner salt (CA INDEX NAME)



RN 918152-11-1 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-3-(3-phenylpropyl)- (CA INDEX NAME)



IT 857067-38-0 857071-29-5

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of 1-[(2-amino-3-(substituted

alkyl)-3H-benzimidazolyl)methyl]-3-substituted-1,3-dihydro-benzimidazol-

2-ones with activity on respiratory syncytial virus)



RN 857067-38-0 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



RN 857071-29-5 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



IT 857070-36-1P 857070-68-9P 857071-34-2P

918152-25-7P 918152-26-8P 918152-27-9P



918152-28-0P 918152-30-4P 918152-31-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 1-[(2-amino-3-(substituted alkyl)-3H-benzimidazolyl)methyl]-3-substituted-1,3-dihydro-benzimidazol-2-ones with activity on respiratory syncytial virus)


RN 857070-36-1 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)





RN 857070-68-9 CAPLUS

CN 3-Pyridinol, 2-[[6-(chloromethyl)-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-, hydrochloride (1:4) (CA INDEX NAME)




● 4 HCl

RN 857071-34-2 CAPLUS
 CN 3-Pyridinol, 2-[[6-(chloromethyl)-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-, hydrochloride (1:4) (CA INDEX NAME)




● 4 HCl


RN 918152-25-7 CAPLUS
 CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[2-(4-morpholinyl)ethyl]amino]- (CA INDEX NAME)



RN 918152-26-8 CAPLUS
 CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[2-(4-morpholinyl)ethyl]amino]- (CA INDEX NAME)




RN 918152-27-9 CAPLUS
 CN 3-Pyridinol, 2-[[6-(chloromethyl)-2-[[2-(4-morpholinyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-, hydrochloride (1:4) (CA INDEX NAME)




● 4 HCl

RN 918152-28-0 CAPLUS
 CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[2-(4-morpholinyl)ethyl]amino]- (CA INDEX NAME)





RN 918152-30-4 CAPLUS
 CN 3-Pyridinol, 2-[[6-(chloromethyl)-2-[[2-(4-morpholinyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-, hydrochloride (1:4) (CA INDEX NAME)




● 4 HCl

RN 918152-31-5 CAPLUS
 CN 3-Pyridinol, 2-[[5-(chloromethyl)-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-, hydrochloride (1:4) (CA INDEX NAME)



● 4 HCl

IT 1062064-57-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of 1-[(2-amino-3-(substituted alkyl)-3H-benzimidazolyl)methyl]-3-substituted-1,3-dihydro-benzimidazole-2-ones with activity on respiratory syncytial virus)
 RN 1062064-57-6 CAPLUS
 CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[2-(4-morpholinyl)ethyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1356649 CAPLUS

DOCUMENT NUMBER: 146:100692

TITLE: Preparation of 2-substituted benzimidazoles as
respiratory syncytial virus (RSV) replication
inhibitors

INVENTOR(S): Bonfanti, Jean-Francois; Muller, Philippe; Fortin,
Jerome Michel Claude; Doublet, Frederic Marc Maurice

PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd, Ire.

SOURCE: PCT Int. Appl., 42pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|------------|
| WO 2006136563 | A1 | 20061228 | WO 2006-EP63367 | 20060620 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| AU 2006260971 | A1 | 20061228 | AU 2006-260971 | 20060620 |
| CA 2612265 | A1 | 20061228 | CA 2006-2612265 | 20060620 |
| EP 1896450 | A1 | 20080312 | EP 2006-777372 | 20060620 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| JP 2008546740 | T | 20081225 | JP 2008-517489 | 20060620 |
| IN 2007DN09650 | A | 20080620 | IN 2007-DN9650 | 20071213 |
| MX 200716313 | A | 20080307 | MX 2007-16313 | 20071217 |
| CN 101203507 | A | 20080618 | CN 2006-80022016 | 20071219 |
| PRIORITY APPLN. INFO.: | | | EP 2005-76440 | A 20050620 |
| | | | WO 2006-EP63367 | W 20060620 |

OTHER SOURCE(S): MARPAT 146:100692

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [Q = H, alkyl optionally substituted with a heterocycle or Q = alkyl substituted with both OR4 and a heterocycle (wherein said heterocycle = oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, etc.); each Alk = alkanediyl; R1 = Ar2 or (un)substituted piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyridyl, etc.; R2 = H or alkyl; R3, R4 = H, alkyl, hydroxyalkyl, etc.; Ar2 = (un)substituted Ph], useful as inhibitors of RSV replication, were prepared E.g., a multi-step synthesis of II, starting with III and IV, was given. Exemplified compds. I were screened in vitro for activity against respiratory syncytial virus (pEC50 values were given). Pharmaceutical

composition comprising the compound I is disclosed.


IT 918155-50-7P 918155-62-1P 918155-63-2P
918155-64-3P 918155-65-4P 918155-66-5P
918155-67-6P 918155-68-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of 2-substituted benzimidazoles as respiratory syncytial virus
(RSV) replication inhibitors)


RN 918155-50-7 CAPLUS

CN Acetamide, N-[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-6-[[2-(3-
hydroxypropyl)-5-methylphenyl]amino]methyl]-1H-benzimidazol-2-yl]- (CA
INDEX NAME)




RN 918155-62-1 CAPLUS

CN Acetamide, N-[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-6-[[2-(3-
hydroxypropyl)phenyl]amino]methyl]-1H-benzimidazol-2-yl]- (CA INDEX NAME)




RN 918155-63-2 CAPLUS

CN Acetamide, N-[6-[[[(3,5-dichlorophenyl)amino]methyl]-1-[(3-hydroxy-6-methyl-
2-pyridinyl)methyl]-1H-benzimidazol-2-yl]- (CA INDEX NAME)




RN 918155-64-3 CAPLUS

CN Acetamide, N-[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-6-[[[(3-
methylphenyl)amino]methyl]-1H-benzimidazol-2-yl]- (CA INDEX NAME)




RN 918155-65-4 CAPLUS

CN Acetamide, N-[6-[(3-ethylphenyl)amino]methyl]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]- (CA INDEX NAME)




RN 918155-66-5 CAPLUS

CN Acetamide, N-[6-[(2,5-dimethylphenyl)amino]methyl]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]- (CA INDEX NAME)




RN 918155-67-6 CAPLUS

CN Acetamide, N-[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-6-[[[2-[2-(4-morpholinyl)ethyl]phenyl]amino]methyl]-1H-benzimidazol-2-yl]- (CA INDEX NAME)



RN 918155-68-7 CAPLUS

CN Benzenepropanamide, 2-[[[2-(acetylamino)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




IT 918155-70-1P 918155-71-2P 918155-72-3P
918155-73-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-substituted benzimidazoles as respiratory syncytial virus (RSV) replication inhibitors)


RN 918155-70-1 CAPLUS

CN Acetamide, N-[6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]- (CA INDEX NAME)




RN 918155-71-2 CAPLUS

CN Acetamide, N-[6-(hydroxymethyl)-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]- (CA INDEX NAME)




RN 918155-72-3 CAPLUS

CN Acetamide, N-[6-formyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]- (CA INDEX NAME)



RN 918155-73-4 CAPLUS

CN Acetamide, N-[6-[[[2-(3-hydroxypropyl)-5-methylphenyl]amino]methyl]-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1355985 CAPLUS

DOCUMENT NUMBER: 146:100688

TITLE: Preparation of heterocyclylaminoalkyl substituted benzimidazoles as respiratory syncytial virus (RSV) replication inhibitors

INVENTOR(S): Bonfanti, Jean-Francois; Muller, Philippe; Fortin, Jerome Michel Claude; Doublet, Frederic Marc Maurice

PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd, Ire.

SOURCE: PCT Int. Appl., 40pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2006136562 | A1 | 20061228 | WO 2006-EP63366 | 20060620 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| AU 2006260970 | A1 | 20061228 | AU 2006-260970 | 20060620 |

| | | | | |
|---|----|----------|--|------------|
| CA 2612264 | A1 | 20061228 | CA 2006-2612264 | 20060620 |
| EP 1896449 | A1 | 20080312 | EP 2006-763809 | 20060620 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| JP 2008546739 | T | 20081225 | JP 2008-517488 | 20060620 |
| MX 200716311 | A | 20080307 | MX 2007-16311 | 20071217 |
| IN 2007DN09755 | A | 20080620 | IN 2007-DN9755 | 20071217 |
| CN 101203506 | A | 20080618 | CN 2006-80021970 | 20071219 |
| PRIORITY APPLN. INFO.: | | | EP 2005-76439 | A 20050620 |
| | | | WO 2006-EP63366 | W 20060620 |
| OTHER SOURCE(S): | | | CASREACT 146:100688; MARPAT 146:100688 | |
| GI | | | | |




AB The title compds. I [Q = H, alkyl optionally substituted with a heterocycle or Q = alkyl substituted with both -OR4 and a heterocycle (wherein said heterocycle = (un)substituted oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, etc.); each Alk = alkanediyl; R1 = Ar or (un)substituted piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyridyl, etc.; R3 = hydroxyalkyl, alkoxyalkyl, cyanoalkyl, etc.; R2, R4 and R5 = H or alkyl; Het = pyridyl, pyrazinyl, pyridazinyl, etc.], useful as inhibitors of RSV replication, were prepared E.g., a multi-step synthesis of II, starting from Et 3,4-diaminobenzoate, was given. Exemplified compds. I were screened in vitro for activity against RSV (pEC50 values were provided). Pharmaceutical composition comprising the compound I is disclosed.

IT 918153-21-6P 918153-22-7P 918153-23-8P
918153-24-9P 918153-25-0P 918153-27-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclylaminoalkyl substituted benzimidazoles as respiratory syncytial virus (RSV) replication inhibitors)



RN 918153-21-6 CAPLUS

CN 2-Pyridineethanol, 3-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 918153-22-7 CAPLUS

CN 2-Pyridineethanol, 3-[[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)





RN 918153-23-8 CAPLUS

CN 4-Pyridineethanol, 3-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 918153-24-9 CAPLUS

CN 4-Pyridineethanol, 3-[[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 918153-25-0 CAPLUS

CN 2-Pyridineethanol, 3-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-5-methyl-
(CA INDEX NAME)



RN 918153-27-2 CAPLUS

CN 2-Pyridineethanol, 3-[[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-5-methyl-
(CA INDEX NAME)



IT 857067-38-0P 857067-39-1P 857070-36-1P


857070-65-6P 857071-29-5P 857071-32-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of heterocyclaminoalkyl substituted benzimidazoles as
respiratory syncytial virus (RSV) replication inhibitors)


RN 857067-38-0 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-
[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857067-39-1 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857070-36-1 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)





RN 857070-65-6 CAPLUS

CN 1H-Benzimidazole-6-carboxaldehyde, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)





RN 857071-29-5 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



RN 857071-32-0 CAPLUS

CN 1H-Benzimidazole-6-carboxaldehyde, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:570884 CAPLUS



DOCUMENT NUMBER: 143:97367

TITLE: Preparation of 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication

INVENTOR(S): Bonfanti, Jean-francois; Andries, Koenraad Jozef Lodewijk; Fortin, Jerome Michel Claude; Muller,

PATENT ASSIGNEE(S): Philippe; Doublet, Frederic Marc Maurice; Meyer, Christophe; Willebrords, Rudy Edmond; Gevers, Tom
 SOURCE: Tibotec Pharmaceuticals Ltd., Ire.
 PCT Int. Appl., 100 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|--------------------------------------|------------------|------------|
| WO 2005058874 | A1 | 20050630 | WO 2004-EP53618 | 20041220 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004298459 | A1 | 20050630 | AU 2004-298459 | 20041220 |
| CA 2548793 | A1 | 20050630 | CA 2004-2548793 | 20041220 |
| EP 1697347 | A1 | 20060906 | EP 2004-804954 | 20041220 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU | | | | |
| CN 1914196 | A | 20070214 | CN 2004-80041654 | 20041220 |
| BR 2004017273 | A | 20070327 | BR 2004-17273 | 20041220 |
| JP 2007514719 | T | 20070607 | JP 2006-544465 | 20041220 |
| IN 2006DN03418 | A | 20070420 | IN 2006-DN3418 | 20060614 |
| US 20070093502 | A1 | 20070426 | US 2006-596521 | 20060615 |
| MX 2006007111 | A | 20060823 | MX 2006-7111 | 20060619 |
| KR 2006127047 | A | 20061211 | KR 2006-714248 | 20060714 |
| PRIORITY APPLN. INFO.: | | | EP 2003-104806 | A 20031218 |
| | | | US 2004-566867P | P 20040430 |
| | | | WO 2004-EP53618 | W 20041220 |
| OTHER SOURCE(S): | | CASREACT 143:97367; MARPAT 143:97367 | | |
| GI | | | | |



AB The title compds. I [Q = Ar2, R6, pyrrolidinyl substituted with R6, piperidinyl substituted with R6 or homopiperidinyl substituted with R6; G = a direct bond or (un)substituted alkanediyl; R1 = Ar1 or a monocyclic or bicyclic heterocycle; one of R2a and R2b = cyanoalkyl, cyanoalkenyl, Ar3(alkyl), Het(alkyl), etc., and the other one of R2a and R2b = H; in case R2a = H, then R3 = H; in case R2b = H, the R3 = H or alkyl; R5 = H, alkyl; R6 = H, (un)substituted alkyl, etc.; Ar1, Ar2 = (un)substituted Ph; Ar3 = (un)substituted Ph, naphthalenyl, 1,2,3,4-tetrahydronaphthalenyl, indanyl; heterocycle; and a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochem. isomeric form thereof] having inhibitory activity on the replication of the respiratory syncytial virus, were prepared E.g., a multi-step synthesis of II, starting from Et 3,4-diaminobenzoate, was given. The exemplified compds. I were tested for activity against RSV (data given). The pharmaceutical composition comprising the compound I is disclosed.


IT 857035-13-3P 857035-18-8P 857035-20-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 5- or 6-substituted benzimidazole derivs. as inhibitors of respiratory syncytial virus replication)


RN 857035-13-3 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(1-piperidinyl)propyl]amino]- (CA INDEX NAME)




RN 857035-18-8 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-
[[3-(1-piperidinyl)propyl]amino]- (CA INDEX NAME)



RN 857035-20-2 CAPLUS

CN 3-Pyridinol, 2-[[2-[[[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-6-
[[3,5-dimethylphenyl]amino]methyl]-1H-benzimidazol-1-yl]methyl]-6-methyl-
(CA INDEX NAME)




IT 857035-09-7P 857035-10-0P 857035-11-1P
857035-12-2P 857035-14-4P 857035-15-5P
857035-16-6P 857035-17-7P 857035-19-9P
857035-21-3P 857035-22-4P 857035-23-5P
857035-24-6P 857035-25-7P 857035-26-8P
857035-27-9P 857035-28-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of 5- or 6-substituted benzimidazole derivs. as inhibitors of
respiratory syncytial virus replication)

RN 857035-09-7 CAPLUS


CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-2-[[3-(1-
piperidinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA
INDEX NAME)



RN 857035-10-0 CAPLUS


CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-2-[[3-(4-methyl-1-
piperazinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA

INDEX NAME)




RN 857035-11-1 CAPLUS

CN 1,2-Propanediol, 3-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 857035-12-2 CAPLUS

CN 3-Pyridinol, 2-[[5-[[[(3,5-dimethylphenyl)amino]methyl]-2-[[3-(1-piperidinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857035-14-4 CAPLUS


CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]- (CA INDEX NAME)




RN 857035-15-5 CAPLUS
 CN 3-Pyridinol, 2-[[5-[[[(3,5-dimethylphenyl)amino]methyl]-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857035-16-6 CAPLUS
 CN 1,2-Propanediol, 3-[[5-[[[(3,5-dimethylphenyl)amino]methyl]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)



RN 857035-17-7 CAPLUS
 CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[2-(4-methoxyphenyl)ethyl]amino]- (CA INDEX NAME)




RN 857035-19-9 CAPLUS
 CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]- (CA INDEX NAME)




RN 857035-21-3 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[(2-phenylethyl)amino]- (CA INDEX NAME)




RN 857035-22-4 CAPLUS

CN 3-Pyridinol, 2-[[5-[[[(3,5-dimethylphenyl)amino]methyl]-2-[(2-phenylethyl)amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857035-23-5 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-2-[(2-phenylethyl)amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857035-24-6 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[(2-phenylethyl)amino]- (CA INDEX NAME)




RN 857035-25-7 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[2-(4-methoxyphenyl)ethyl]amino]- (CA INDEX NAME)




RN 857035-26-8 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-2-[[2-(4-methoxyphenyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl]- (CA INDEX NAME)




RN 857035-27-9 CAPLUS

CN 3-Pyridinol, 2-[[5-[[[(3,5-dimethylphenyl)amino]methyl]-2-[[2-(4-methoxyphenyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl]- (CA INDEX NAME)




RN 857035-28-0 CAPLUS


CN 3-Pyridinol, 2-[[6-[[[(3,5-dichlorophenyl)amino]methyl]-2-[[2-(4-methoxyphenyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl]- (CA INDEX NAME)




IT 857035-58-6P 857035-59-7P 857035-60-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of 5- or 6-substituted benzimidazole derivs. as inhibitors of
 respiratory syncytial virus replication)
 RN 857035-58-6 CAPLUS
 CN 1H-Benzimidazole-6-carboxylic acid,
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(1-
 piperidinyl)propyl]amino]-, ethyl ester (CA INDEX NAME)



RN 857035-59-7 CAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid,
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(1-
 piperidinyl)propyl]amino]-, ethyl ester (CA INDEX NAME)



RN 857035-60-0 CAPLUS
 CN 1H-Benzimidazole-6-carboxaldehyde,
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(1-
 piperidinyl)propyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:570883 CAPLUS

DOCUMENT NUMBER: 143:97366

TITLE: Preparation of aminobenzimidazoles as inhibitors of respiratory syncytial virus replication

INVENTOR(S): Bonfanti, Jean-francois; Andries, Koenraad Jozef Lodewijk; Fortin, Jerome Michel Claude; Muller, Philippe; Doublet, Frederic Marc Maurice; Meyer, Christophe; Willebrords, Rudy Edmond; Gevers, Tom Valerius Josepha; Timmerman, Philip Maria Martha Bern

PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.

SOURCE: PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|------------------|------------|
| WO 2005058869 | A1 | 20050630 | WO 2004-EP53613 | 20041220 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| AU 2004298457 | A1 | 20050630 | AU 2004-298457 | 20041220 |
| CA 2548657 | A1 | 20050630 | CA 2004-2548657 | 20041220 |
| EP 1697343 | A1 | 20060906 | EP 2004-804949 | 20041220 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU | | | |
| CN 1918146 | A | 20070221 | CN 2004-80041689 | 20041220 |
| BR 2004017811 | A | 20070327 | BR 2004-17811 | 20041220 |
| JP 2007514717 | T | 20070607 | JP 2006-544463 | 20041220 |
| IN 2006DN03296 | A | 20070420 | IN 2006-DN3296 | 20060608 |
| US 20070099924 | A1 | 20070503 | US 2006-596514 | 20060615 |
| MX 2006007108 | A | 20060818 | MX 2006-7108 | 20060619 |
| NO 2006003218 | A | 20060711 | NO 2006-3218 | 20060711 |
| KR 2006127879 | A | 20061213 | KR 2006-714232 | 20060714 |
| PRIORITY APPLN. INFO.: | | | EP 2003-104797 | A 20031218 |

US 2004-566834P


P 20040430

WO 2004-EP53613


W 20041220

OTHER SOURCE(S):
GI

CASREACT 143:97366; MARPAT 143:97366



I



II

AB The title compds. I [G = a direct bond or (un)substituted alkanediyl; R1 = Ar1 or a monocyclic or bicyclic heterocycle; Q = H, amino or mono- or dialkylamino; one of R2a and R3a = halo, optionally mono- or polysubstituted alkyl, optionally mono- or polysubstituted alkenyl, nitro, hydroxy, etc.; and the other one of R2a and R3a = H; in case R2a is different from hydrogen then R2b = H, alkyl or halogen and R3b = H; in case R3a is different from hydrogen then R3b = H, alkyl or halogen and R2b = H; R5 is not defined; Ar1 = (un)substituted Ph; and the prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochem. isomeric forms thereof] having inhibitory activity on RSV replication, were prepared E.g., a multi-step synthesis of II, starting from Et 2-aminobenzimidazole-5-carboxylate, was given. The exemplified compds. I were tested for activity against RSV (data given). The pharmaceutical composition comprising the compound I is disclosed.

IT 856835-30-8P 856835-51-3P 856835-58-0P


856835-64-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminobenzimidazoles as inhibitors of respiratory syncytial virus replication)


RN 856835-30-8 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[(2-hydroxyethyl)(3-methylphenyl)amino]methyl]-2-(methylamino)-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856835-51-3 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-(methylamino)- (CA INDEX NAME)




RN 856835-58-0 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-(methylamino)- (CA INDEX NAME)



RN 856835-64-8 CAPLUS

CN 3-Pyridinol, 2-[[5-[[[(2-hydroxyethyl)(3-methylphenyl)amino]methyl]-2-(methylamino)-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




IT 1060720-96-8P 1060721-93-8P 1060729-12-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminobenzimidazoles as inhibitors of respiratory syncytial virus replication)


RN 1060720-96-8 CAPLUS

CN 1H-Benzimidazole-6-carboxylic acid, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[(methoxycarbonyl)amino]-, ethyl ester (CA INDEX NAME)




RN 1060721-93-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid,
1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[(methoxycarbonyl)amino]-,
ethyl ester (CA INDEX NAME)



RN 1060729-12-5 CAPLUS
CN 3-Pyridinol, 2-[[6-(chloromethyl)-2-(methylamino)-1H-benzimidazol-1-yl]methyl]-6-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:564655 CAPLUS

DOCUMENT NUMBER: 143:97374

TITLE: Preparation of morpholine containing benzimidazoles as inhibitors of respiratory syncytial virus replication

INVENTOR(S): Bonfanti, Jean-Francois; Andries, Koenraad Jozef Lodewijk; Fortin, Jerome Michel Claude; Muller, Philippe; Doublet, Frederic Marc Maurice; Meyer, Christophe; Willebrords, Rudy Edmond; Gevers, Tom Valerius Josepha; Timmerman, Philip Maria Martha Bern

PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.

SOURCE: PCT Int. Appl., 144 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2005058871 | A1 | 20050630 | WO 2004-EP53620 | 20041220 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, | | | | |

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

| | | | | |
|---------------|----|----------|-----------------|----------|
| AU 2004298460 | A1 | 20050630 | AU 2004-298460 | 20041220 |
| CA 2548668 | A1 | 20050630 | CA 2004-2548668 | 20041220 |
| EP 1697345 | A1 | 20060906 | EP 2004-817576 | 20041220 |
| EP 1697345 | B1 | 20080312 | | |



R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
 HR, IS, YU, BA

| | | | | |
|----------------|----|----------|------------------|----------|
| CN 1894237 | A | 20070110 | CN 2004-80037825 | 20041220 |
| BR 2004017268 | A | 20070313 | BR 2004-17268 | 20041220 |
| JP 2007514720 | T | 20070607 | JP 2006-544467 | 20041220 |
| AT 388950 | T | 20080315 | AT 2004-817576 | 20041220 |
| ES 2303653 | T3 | 20080816 | ES 2004-817576 | 20041220 |
| US 20070043022 | A1 | 20070222 | US 2006-563691 | 20060104 |
| US 7449463 | B2 | 20081111 | | |
| IN 2006DN03140 | A | 20070824 | IN 2006-DN3140 | 20060601 |
| MX 2006007112 | A | 20060823 | MX 2006-7112 | 20060619 |
| KR 2007015507 | A | 20070205 | KR 2006-714047 | 20060712 |
| NO 2006003322 | A | 20060918 | NO 2006-3322 | 20060718 |
| US 20080280881 | A1 | 20081113 | US 2008-140686 | 20080617 |

PRIORITY APPLN. INFO.:

| | | |
|-----------------|----|----------|
| EP 2003-104810 | A | 20031218 |
| US 2004-567182P | P | 20040430 |
| EP 2004-105312 | A | 20041026 |
| WO 2004-EP53620 | W | 20041220 |
| US 2006-563691 | A1 | 20060104 |

OTHER SOURCE(S): CASREACT 143:97374; MARPAT 143:97374
 GI



AB The title compds. I [G = a direct bond or (un)substituted alkanediyl; R1 = Ar1 or a monocyclic or bicyclic heterocycle; Q = R7, pyrrolidinyl

substituted with R7, piperidinyl substituted with R7 or homopiperidinyl substituted with R7; one of R2a and R3a = halo, optionally mono- or polysubstituted alkyl, optionally mono- or polysubstituted alkenyl, nitro, hydroxy, etc.; and the other one of R2a and R3a = H; in case R2a is different from H atom then R2b = H, alkyl or halogen and R3b = H; in case R3a is different from H atom then R3b = H, alkyl or halogen and R2b = H; R5 = H, alkyl; Ar1 = (un)substituted Ph; R7 = alkyl substituted with heterocycle or alkyl substituted with both a radical OR8 and a heterocycle; R8 = H, alkyl, Arylalkyl; or a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochem. isomeric form thereof] having inhibitory activity on the replication of the respiratory syncytial virus, were prepared E.g., a multi-step synthesis of II, starting from Et 3,4-diaminobenzoate, was given. The compds. I were tested for activity against RSV (data given). The pharmaceutical composition comprising the

compound

I is disclosed.


IT 857067-38-0P 857067-39-1P 857068-61-2P
857069-72-8P 857070-23-6P 857070-36-1P
857070-37-2P 857070-98-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of morpholine containing benzimidazoles as inhibitors of respiratory syncytial virus replication)


RN 857067-38-0 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



RN 857067-39-1 CAPLUS


CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



RN 857068-61-2 CAPLUS



CN 1H-Benzimidazole-6-methanol, 2-[[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]propyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 857069-72-8 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(6-bromo-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)





RN 857070-23-6 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857070-36-1 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



RN 857070-37-2 CAPLUS


CN 1H-Benzimidazole-5-methanol, 1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



RN 857070-98-5 CAPLUS

CN 1H-Benzimidazole-5-methanol, 2-[[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]propyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 857066-88-7P 857066-89-8P 857066-90-1P
 857066-91-2P 857066-92-3P 857066-93-4P
 857066-94-5P 857066-95-6P 857066-96-7P
 857066-97-8P 857066-98-9P 857066-99-0P
 857067-00-6P 857067-01-7P 857067-02-8P
 857067-03-9P 857067-04-0P 857067-05-1P

| | | |
|--------------|--------------|--------------|
| 857067-06-2P | 857067-07-3P | 857067-08-4P |
| 857067-09-5P | 857067-10-8P | 857067-11-9P |
| 857067-12-0P | 857067-13-1P | 857067-14-2P |
| 857067-15-3P | 857067-16-4P | 857067-17-5P |
| 857067-18-6P | 857067-19-7P | 857067-20-0P |
| 857067-21-1P | 857067-22-2P | 857067-23-3P |
| 857067-24-4P | 857067-25-5P | 857067-26-6P |
| 857067-27-7P | 857067-28-8P | 857067-29-9P |
| 857067-30-2P | 857067-31-3P | 857067-32-4P |
| 857067-33-5P | 857067-34-6P | 857067-35-7P |
| 857067-36-8P | 857067-37-9P | 857067-40-4P |
| 857067-41-5P | 857067-42-6P | 857067-43-7P |
| 857067-44-8P | 857067-45-9P | 857067-46-0P |
| 857067-47-1P | 857067-48-2P | 857067-49-3P |
| 857067-50-6P | 857067-51-7P | 857067-52-8P |
| 857067-53-9P | 857067-54-0P | 857067-55-1P |
| 857067-56-2P | 857067-57-3P | 857067-58-4P |
| 857067-59-5P | 857067-60-8P | 857067-61-9P |
| 857067-62-0P | 857067-63-1P | 857067-64-2P |
| 857067-65-3P | 857067-66-4P | 857067-67-5P |
| 857067-68-6P | 857067-69-7P | 857067-70-0P |
| 857067-71-1P | 857067-72-2P | 857067-73-3P |
| 857067-74-4P | 857067-75-5P | 857067-76-6P |
| 857067-77-7P | 857067-78-8P | 857067-79-9P |
| 857067-80-2P | 857067-81-3P | 857067-82-4P |
| 857067-83-5P | 857067-84-6P | 857067-85-7P |
| 857067-86-8P | 857067-87-9P | 857067-88-0P |
| 857067-89-1P | 857067-90-4P | 857067-91-5P |
| 857067-92-6P | 857067-93-7P | 857067-94-8P |
| 857067-95-9P | 857067-96-0P | 857067-97-1P |
| 857067-98-2P | 857067-99-3P | 857068-00-9P |
| 857068-01-0P | 857068-02-1P | 857068-03-2P |
| 857068-04-3P | 857068-05-4P | 857068-06-5P |
| 857068-07-6P | 857068-08-7P | 857068-09-8P |
| 857068-10-1P | 857068-11-2P | 857068-12-3P |
| 857068-13-4P | 857068-14-5P | 857068-15-6P |
| 857068-16-7P | 857068-17-8P | 857068-18-9P |
| 857068-19-0P | 857068-20-3P | 857068-21-4P |
| 857068-22-5P | 857068-23-6P | 857068-24-7P |
| 857068-25-8P | 857068-26-9P | 857068-27-0P |
| 857068-28-1P | 857068-29-2P | 857068-30-5P |
| 857068-31-6P | 857068-32-7P | 857068-33-8P |
| 857068-34-9P | 857068-35-0P | 857068-36-1P |
| 857068-37-2P | 857068-38-3P | 857068-39-4P |
| 857068-40-7P | 857068-41-8P | 857068-42-9P |
| 857068-43-0P | 857068-44-1P | 857068-45-2P |
| 857068-46-3P | 857068-57-6P | 857068-58-7P |
| 857068-59-8P | 857068-60-1P | 857068-62-3P |
| 857068-63-4P | 857068-64-5P | 857068-65-6P |
| 857068-66-7P | 857068-67-8P | 857068-68-9P |
| 857068-70-3P | 857068-71-4P | 857068-72-5P |
| 857068-81-6P | 857068-88-3P | 857068-94-1P |
| 857068-97-4P | 857068-98-5P | 857069-06-8P |
| 857069-17-1P | 857069-18-2P | 857069-25-1P |
| 857069-26-2P | 857069-29-5P | 857069-37-5P |
| 857069-38-6P | 857069-41-1P | 857069-43-3P |
| 857069-44-4P | 857069-47-7P | 857069-48-8P |
| 857069-50-2P | 857069-51-3P | 857069-54-6P |
| 857069-55-7P | 857069-56-8P | 857069-57-9P |
| 857069-75-1P | 857069-76-2P | 857069-79-5P |
| 857069-80-8P | 857069-81-9P | 857069-83-1P |
| 857069-84-2P | 857069-91-1P | 857069-97-7P |


857070-00-9P 857070-04-3P 857070-09-8P
 857070-10-1P 857070-11-2P 857070-12-3P
 857070-15-6P 857070-18-9P 857070-19-0P
 857070-20-3P 857070-21-4P 857070-22-5P
 857070-24-7P 857070-25-8P 857070-27-0P
 857070-29-2P 857070-30-5P 857070-34-9P
 857070-40-7P 857070-41-8P 857070-43-0P
 857070-59-8P 857070-60-1P 857070-61-2P
 857071-23-9P 857083-26-2P 857083-27-3P
 857083-28-4P 857083-29-5P 857083-30-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of morpholine containing benzimidazoles as inhibitors of respiratory syncytial virus replication)


RN 857066-88-7 CAPLUS

CN Benzonitrile, 4-(2-hydroxyethyl)-3-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857066-89-8 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[5-bromo-2-(3-hydroxypropyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857066-90-1 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[2-(3-hydroxypropyl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857066-91-2 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[5-chloro-2-(3-hydroxypropyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
(CA INDEX NAME)




RN 857066-92-3 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethoxy)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
(CA INDEX NAME)




RN 857066-93-4 CAPLUS


CN 3-Pyridinol, 2-[[6-[[[5-ethenyl-2-(2-hydroxyethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
(CA INDEX NAME)




RN 857066-94-5 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
 (CA INDEX NAME)




RN 857066-95-6 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[2-(3-hydroxypropyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA
 INDEX NAME)




RN 857066-96-7 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)-5-methoxyphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
 (CA INDEX NAME)




RN 857066-97-8 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[5-bromo-2-(2-hydroxyethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA
 INDEX NAME)




| | | |
|----|---|--------|
| RN | 857066-98-9 | CAPLUS |
| CN | 3-Pyridinol, 2-[[6-[[[2-[(2-hydroxyethyl)sulfonyl]-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME) | |



| | | |
|----|---|--------|
| RN | 857066-99-0 | CAPLUS |
| CN | 3-Pyridinol, 2-[[6-[[[2-(3-hydroxypropyl)-5-(trifluoromethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME) | |




| | | |
|----|--|--------|
| RN | 857067-00-6 | CAPLUS |
| CN | 3-Pyridinol, 2-[[6-[[[2-(3-hydroxypropyl)-5-methoxyphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-(CA INDEX NAME) | |




RN 857067-01-7 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(3-hydroxybutyl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-02-8 CAPLUS

CN Benzenepropanamide, 2-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-4-methyl- (CA INDEX NAME)




RN 857067-03-9 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)-5-(1-methylethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-04-0 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[5-fluoro-2-(2-hydroxyethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-05-1 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(3-hydroxy-1-propen-1-yl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-06-2 CAPLUS


CN 3-Pyridinol, 2-[[6-[[[2-(4-hydroxybutyl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-07-3 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[(3,5-dichlorophenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-08-4 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857067-09-5 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-10-8 CAPLUS
 CN Benzenepropanamide, 2-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 857067-11-9 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)-3-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-12-0 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[3-bromophenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-13-1 CAPLUS

CN Benzonitrile, 2-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-14-2 CAPLUS

CN 3-Pyridinol, 6-methyl-2-[[6-[[3-(4-methylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-15-3 CAPLUS

CN 3-Pyridinol, 2-[[6-[[2-(hydroxymethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-16-4 CAPLUS

CN 3-Pyridinol, 2-[[6-[[3-(ethynylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-17-5 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3-chlorophenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-18-6 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(hydroxymethyl)-4-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-19-7 CAPLUS

CN Benzenepropanamide, 2-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-20-0 CAPLUS


CN 3-Pyridinol, 2-[[6-[[[2-(3-hydroxy-1-propyn-1-yl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-21-1 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[(3-fluorophenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-22-2 CAPLUS
 CN 3-Pyridinol, 6-methyl-2-[[2-[[3-(4-morpholinyl)propyl]amino]-6-[[[3-(trifluoromethoxy)phenyl]amino]methyl]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 857067-23-3 CAPLUS
 CN Benzenesulfonamide, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-24-4 CAPLUS
 CN Benzamide, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-25-5 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[2-[(2-hydroxyethyl)amino]-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-26-6 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[2-(2,5-dimethylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-27-7 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[2-(2-ethylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-28-8 CAPLUS
 CN 3-Pyridinol, 6-methyl-2-[[6-[[[2-[2-(4-morpholinyl)ethyl]phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)



RN 857067-29-9 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[2-(hydroxymethyl)-3-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-30-2 CAPLUS
 CN Benzamide, 4-(2-hydroxyethyl)-3-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-31-3 CAPLUS

CN Benzamide, 2-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-4-(2-hydroxyethyl)- (CA INDEX NAME)




RN 857067-32-4 CAPLUS

CN Benzenepropanenitrile, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-3-methyl- (CA INDEX NAME)




RN 857067-33-5 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[3-(2-hydroxyethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-4-(2-cyanoethyl)phenyl]- (CA INDEX NAME)




RN 857067-34-6 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)-5-(methylsulfonyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-35-7 CAPLUS

CN Benzenepropanenitrile, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-3,5-dimethyl- (CA INDEX NAME)




RN 857067-36-8 CAPLUS


CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)-5-(methylsulfonyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-37-9 CAPLUS
 CN 3-Pyridinol, 2-[[5-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857067-40-4 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)-5-(3-thienyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-41-5 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[5-(3-furanyl)-2-(2-hydroxyethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-42-6 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)-5-(2-thienyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
(CA INDEX NAME)




RN 857067-43-7 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[5-(2-furanyl)-2-(2-hydroxyethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
(CA INDEX NAME)




RN 857067-44-8 CAPLUS


CN 3-Pyridinol, 2-[[6-[[[3,5-dimethylphenyl](2-hydroxyethyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
(CA INDEX NAME)




RN 857067-45-9 CAPLUS
 CN Butanamide, 4-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)



RN 857067-46-0 CAPLUS
 CN Propanamide, 3-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-47-1 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)(4-hydroxybutyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-48-2 CAPLUS

CN Butanoic acid, 4-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-49-3 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)(3-hydroxypropyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-50-6 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)(5-hydroxypentyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-51-7 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)[2-(4-morpholinyl)ethyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-52-8 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(2-aminoethyl)(3,5-dimethylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-53-9 CAPLUS

CN Phosphoric acid, 2-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]ethyl diethyl ester (CA INDEX NAME)




RN 857067-54-0 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)[3-(4-morpholinyl)propyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-55-1 CAPLUS

CN β -Alanine, N-(3,5-dimethylphenyl)-N-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]- (CA INDEX NAME)




RN 857067-56-2 CAPLUS

CN Phosphonic acid, [2-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]ethyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 857067-57-3 CAPLUS

CN Butanoic acid, 4-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-, ethyl ester (CA INDEX NAME)




RN 857067-58-4 CAPLUS

CN β -Alanine, N-(3,5-dimethylphenyl)-N-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-, ethyl ester (CA INDEX NAME)




RN 857067-59-5 CAPLUS

CN 1-Propanesulfonamide, 3-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-60-8 CAPLUS

CN 1-Butanesulfonamide, 4-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-61-9 CAPLUS

CN Pentanamide, 5-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-62-0 CAPLUS


CN 1-Propanesulfonamide, 3-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-N-methyl- (CA INDEX NAME)




RN 857067-63-1 CAPLUS
 CN Butanamide, 4-[[3,5-dimethylphenyl][[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-N-methyl- (CA INDEX NAME)




RN 857067-64-2 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[3,5-dimethylphenyl](2-hydroxy-3-methylbutyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-65-3 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[3,5-dimethylphenyl][2-(2-hydroxyethoxy)ethyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-66-4 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)(2-hydroxy-3-phenoxypropyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-67-5 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)(1H-imidazol-5-ylmethyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857067-68-6 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)(2-methoxyethyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-69-7 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[3,5-dimethylphenyl](2-hydroxy-3-phenylpropyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 857067-70-0 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[3,5-dimethylphenyl](2-hydroxy-3,3-dimethylbutyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-71-1 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[3-bromophenyl](2-hydroxyethyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-72-2 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)(3-methylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-73-3 CAPLUS

CN Butanamide, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl](3-methylphenyl)amino]- (CA INDEX NAME)




RN 857067-74-4 CAPLUS

CN Benzonitrile, 4-[(2-hydroxyethyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-75-5 CAPLUS

CN Propanamide, 3-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl](3-methylphenyl)amino]- (CA INDEX NAME)




RN 857067-76-6 CAPLUS

CN Butanamide, 4-[(3-bromophenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-77-7 CAPLUS

CN 1-Butanesulfonamide, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl](3-methylphenyl)amino]- (CA INDEX NAME)




RN 857067-78-8 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(4-hydroxybutyl)(3-methylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-79-9 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3-hydroxypropyl)(3-methylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-80-2 CAPLUS

CN 3-Pyridinol, 6-methyl-2-[[6-[[[(3-methylphenyl)[2-(4-morpholinyl)ethyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-81-3 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[(3-bromophenyl)(3-hydroxypropyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-82-4 CAPLUS

CN Butanamide, 4-[[[4-cyanophenyl][[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-83-5 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[(2-hydroxyethyl)phenylamino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-84-6 CAPLUS

CN 1-Propanesulfonamide, 3-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl](3-methylphenyl)amino]-N-methyl- (CA INDEX NAME)




RN 857067-85-7 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[3-(ethynylphenyl)(2-hydroxyethyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-86-8 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[2-(dimethylamino)ethyl](3-methylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-87-9 CAPLUS

CN Acetamide, 2-[2-(2-hydroxyethyl)phenyl][1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl)methyl]amino]- (CA INDEX NAME)




RN 857067-88-0 CAPLUS

CN Butanoic acid, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl](3-methylphenyl)amino]-, methyl ester (CA INDEX NAME)




RN 857067-89-1 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[2-(2-hydroxyethyl)phenyl][2-(4-morpholinyl)ethyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-90-4 CAPLUS

CN Propanamide, 3-[[3-(2-hydroxyethyl)phenyl][[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-91-5 CAPLUS

CN Benzamide, 4-[(2-hydroxyethyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-92-6 CAPLUS


CN 3-Pyridinol, 2-[[[6-[[[4-(hydroxyphenyl)phenylamino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl]- (CA INDEX NAME)




RN 857067-93-7 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857067-94-8 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[2-(aminomethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-95-9 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[(3-hydroxyphenyl)phenylamino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-96-0 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)(2-methylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857067-97-1 CAPLUS

CN Benzamide, 2-[(2-hydroxyethyl) [[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-98-2 CAPLUS

CN 1-Propanesulfonamide, 3-[(3-ethynylphenyl) [[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857067-99-3 CAPLUS

CN Propanamide, 3-[(3-bromophenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857068-00-9 CAPLUS

CN Butanamide, 4-[(3-ethynylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857068-01-0 CAPLUS

CN Propanamide, 3-[(3-ethynylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857068-02-1 CAPLUS

CN Butanoic acid, 4-[(3-ethynylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857068-03-2 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3-bromophenyl)(4-hydroxybutyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl]- (CA INDEX NAME)




RN 857068-04-3 CAPLUS

CN Propanamide, 3-[(4-cyanophenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857068-05-4 CAPLUS

CN Benzonitrile, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl](3-hydroxypropyl)amino]- (CA INDEX NAME)




RN 857068-06-5 CAPLUS

CN Benzenesulfonamide, 4-[(2-hydroxyethyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857068-07-6 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-3-pyridinol][[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857068-08-7 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)phenyl]methylamino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857068-09-8 CAPLUS

CN Butanamide, 4-[(3,5-dichlorophenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857068-10-1 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(3,5-dichlorophenyl)(4-hydroxybutyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857068-11-2 CAPLUS

CN Propanamide, 3-[[2,5-dimethylphenyl][[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)



RN 857068-12-3 CAPLUS

CN Butanamide, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl][2-methyl-5-(1-methylethyl)phenyl]amino]-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 857068-13-4 CAPLUS


CN Butanamide, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl][2,3,5-

trimethylphenyl)amino]- (CA INDEX NAME)




RN 857068-14-5 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(2,5-dimethylphenyl)(2-hydroxyethyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857068-15-6 CAPLUS


CN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)[2-methyl-5-(1-methylethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857068-16-7 CAPLUS


CN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)(2,3,5-trimethylphenyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-

(CA INDEX NAME)




RN 857068-17-8 CAPLUS

CN Butanamide, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-3-quinolinylamino]-
(CA INDEX NAME)




RN 857068-18-9 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[2-hydroxyethyl)-3-quinolinylamino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
(CA INDEX NAME)




RN 857068-19-0 CAPLUS

CN Butanamide, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2-pyrimidinylamino]-
(CA INDEX NAME)




RN 857068-20-3 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(2-hydroxyethyl)-2-pyrimidinylamino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857068-21-4 CAPLUS

CN Butanamide, 4-[(1-ethyl-1H-pyrazol-5-yl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857068-22-5 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[(1-ethyl-1H-pyrazol-5-yl)(2-hydroxyethyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857068-23-6 CAPLUS

CN Butanamide, 4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-4-pyridinylamino]- (CA INDEX NAME)




RN 857068-24-7 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[(2-hydroxyethyl)(5-methyl-3-isoxazolyl)amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-2-pyridinyl]amino]- (CA INDEX NAME)




RN 857068-25-8 CAPLUS


CN Butanoic acid, 4-[[[4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-3,5-dimethylphenyl]amino]-, ethyl ester (CA INDEX NAME)




RN 857068-26-9 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[4-[(2-hydroxyethyl)amino]-3-methylphenyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
 (CA INDEX NAME)




RN 857068-27-0 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[4-[(2-hydroxyethyl)amino]-3-methoxyphenyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
 (CA INDEX NAME)



RN 857068-28-1 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[4-[(4-hydroxybutyl)amino]-2-methylphenyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
 (CA INDEX NAME)





RN 857068-29-2 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[4-[(2-hydroxyethyl)amino]-2,6-dimethylphenyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857068-30-5 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[2,6-dimethyl-4-[[2-(4-morpholinyl)ethyl]amino]phenyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)

PAGE 1-A







RN 857068-31-6 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[4-[[2-(dimethylamino)ethyl]amino]-2,6-dimethylphenyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857068-32-7 CAPLUS
 CN Benzoic acid, 2-[(2-hydroxyethyl)amino]-5-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-, ethyl ester (CA INDEX NAME)




RN 857068-33-8 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[4-[(4-hydroxybutyl)amino]-2,6-dimethylphenyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 857068-34-9 CAPLUS


CN 1-Propanesulfonamide, 3-[[4-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-3,5-dimethylphenyl]amino]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 857068-35-0 CAPLUS


CN 3-Pyridinol, 2-[[6-[[4-[[1-(hydroxymethyl)propyl]amino]-2,6-dimethylphenyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl


RN 857068-36-1 CAPLUS

CN Propanamide, 3-[[4-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]-2,5-dimethylphenyl]amino]- (CA INDEX NAME)




RN 857068-37-2 CAPLUS

CN 3-Pyridinol, 2-[[6-[[4-[(2-hydroxyethyl)amino]-2,5-dimethylphenyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857068-38-3 CAPLUS


CN 3-Pyridinol, 2-[[6-[[1-ethyl-5-[(2-hydroxyethyl)amino]-1H-pyrazol-4-yl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857068-39-4 CAPLUS
 CN 3-Pyridinol, 2-[[[6-[(2,3-dihydro-6-methyl-1H-indol-1-yl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857068-40-7 CAPLUS
 CN 3-Pyridinol, 2-[[[4,6-dimethyl-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857068-41-8 CAPLUS
 CN 3-Pyridinol, 6-methyl-2-[[[2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 857068-42-9 CAPLUS

CN 3-Pyridinol, 2-[[5,7-dimethyl-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 857068-43-0 CAPLUS

CN 1H-Benzimidazole-6-carboxamide, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-N-[2-(3-hydroxypropyl)-5-methylphenyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857068-44-1 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-N-(3-methylphenyl)-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857068-45-2 CAPLUS


CN 1H-Benzimidazole-6-carboxamide, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-N-(3-methylphenyl)-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



RN 857068-46-3 CAPLUS
 CN 1H-Benzimidazole-6-carboxamide, N-(3,5-dimethylphenyl)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857068-57-6 CAPLUS
 CN 4-Morpholineethanol, α-[[[6-[[3-(3,5-dimethylphenyl)amino]methyl]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]- (CA INDEX NAME)



RN 857068-58-7 CAPLUS
 CN 3-Pyridinol, 2-[[2-[[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]propyl]amino]-6-[[3-(3,5-dimethylphenyl)amino]methyl]-1H-benzimidazol-1-yl]methyl]-6-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 857068-59-8 CAPLUS


CN 3-Pyridinol, 2-[[2-[[3-[(2R,6R)-2,6-dimethyl-4-morpholinyl]propyl]amino]-6-[[3,5-dimethylphenyl]amino]methyl]-1H-benzimidazol-1-yl]methyl]-6-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 857068-60-1 CAPLUS


CN 3-Pyridinol, 2-[[6-[[[3,5-dimethylphenyl]amino]methyl]-2-[[3-(tetrahydro-1,4-oxazepin-4(5H)-yl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857068-62-3 CAPLUS

CN 3-Pyridinol, 6-methyl-2-[[2-[[2-(4-morpholinyl)ethyl]amino]-1H-


benzimidazol-1-yl]methyl]- (CA INDEX NAME)



RN 857068-63-4 CAPLUS


CN 1H-Benzimidazole-6-methanol, 2-[[3-[(2R,6R)-2,6-dimethyl-4-morpholinyl]propyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 857068-64-5 CAPLUS


CN Butanamide, 4-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[2-hydroxy-3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-, hydrochloride (1:4) (CA INDEX NAME)



RN 857068-65-6 CAPLUS
 CN 3-Pyridinol, 2-[[6-[[[(3,5-dimethylphenyl)(2-hydroxyethyl)amino]methyl]-2-
 [[3-(4-thiomorpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-
 (CA INDEX NAME)




RN 857068-66-7 CAPLUS
 CN 4-Morpholineethanol, α -[[[6-[[[(3-bromophenyl)(2-hydroxyethyl)amino]methyl]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 857068-67-8 CAPLUS
 CN 2-Morpholineethanol, 4-[3-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]propyl]-
 (CA INDEX NAME)




RN 857068-68-9 CAPLUS
 CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-
 [[3-(4-thiomorpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857068-70-3 CAPLUS

CN 2-Morpholineethanol, 4-[3-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4,6-dimethyl-1H-benzimidazol-2-yl]amino]propyl]- (CA INDEX NAME)




RN 857068-71-4 CAPLUS

CN 2-Morpholineacetamide, 4-[3-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4,6-dimethyl-1H-benzimidazol-2-yl]amino]propyl]- (CA INDEX NAME)




RN 857068-72-5 CAPLUS

CN 3-Pyridinol, 2-[[6-[[[2-(2-hydroxyethyl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 857068-81-6 CAPLUS

CN Benzonitrile, 4-(2-hydroxyethyl)-3-[[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857068-88-3 CAPLUS

CN Butanamide, 4-[(3,5-dimethylphenyl)[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857068-94-1 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[2-(3-hydroxypropyl)-5-(trifluoromethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 857068-97-4 CAPLUS

CN Benzenepropanol, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-4-methyl- (CA INDEX NAME)






RN 857068-98-5 CAPLUS


CN Benzeneethanol, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-4-methyl- (CA INDEX NAME)




RN 857069-06-8 CAPLUS

CN Butanamide, 4-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)







RN 857069-26-2 CAPLUS
 CN Butanamide, 4-[[[1-[(3,5-dimethylphenyl)[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)



RN 857069-29-5 CAPLUS
 CN Benzeneethanol, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857069-37-5 CAPLUS
 CN Butanamide, 4-[[[1-[(6-bromo-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl] (3,5-dimethylphenyl)amino]- (CA INDEX NAME)




RN 857069-38-6 CAPLUS

CN 1H-Benzimidazole-6-methanamine, N-(2,5-dimethylphenyl)-1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857069-41-1 CAPLUS

CN Benzenepropanamide, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857069-43-3 CAPLUS

CN Benzenepropanol, 2-[[[1-[(6-bromo-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-4-methyl- (CA INDEX NAME)




RN 857069-44-4 CAPLUS

CN 1H-Benzimidazole-6-methanamine, 1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-N-[2-[2-(4-morpholinyl)ethyl]phenyl]-2-[[3-(4-morpholinyl)propyl]amino]-(CA INDEX NAME)




RN 857069-47-7 CAPLUS

CN 1H-Benzimidazole-6-methanamine, N-(3,5-dimethylphenyl)-1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-(CA INDEX NAME)




RN 857069-48-8 CAPLUS

CN Benzenesulfonamide, 4-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-(CA INDEX NAME)




RN 857069-50-2 CAPLUS

CN Benzenepropanol, 4-methyl-2-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857069-51-3 CAPLUS

CN Benzeneethanol, 4-methyl-2-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)



RN 857069-54-6 CAPLUS


CN Ethanol, 2-[[[1-[(6-bromo-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)



●x HCl


RN 857069-55-7 CAPLUS

CN Benzenemethanol, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-5-methyl- (CA INDEX NAME)




RN 857069-56-8 CAPLUS

CN Benzenemethanol, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-5-methyl- (CA INDEX NAME)




RN 857069-57-9 CAPLUS

CN Ethanol, 2-[(3,5-dimethylphenyl)[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857069-75-1 CAPLUS

CN 1H-Benzimidazole-6-methanamine, N-(3-bromophenyl)-1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857069-76-2 CAPLUS

CN Benzenemethanol, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-6-methyl- (CA INDEX NAME)




RN 857069-79-5 CAPLUS

CN 3-Pyridinol, 2-[[[5-[[2-(3-hydroxypropyl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 857069-80-8 CAPLUS

CN Benzamide, 4-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857069-81-9 CAPLUS

CN Benzamide, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857069-83-1 CAPLUS

CN Benzonitrile, 3-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857069-84-2 CAPLUS

CN Benzeneethanol, 3-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857069-91-1 CAPLUS

CN 1H-Benzimidazole-6-methanamine, 1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-N-(3-methylphenyl)-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857069-97-7 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[[3-(2-methoxyethoxy)-6-methyl-2-pyridinyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)





RN 857070-00-9 CAPLUS

CN 1H-Benzimidazole-6-methanamine, N-(2,5-dimethylphenyl)-1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857070-04-3 CAPLUS

CN 3-Pyridinol, 2-[[[6-[[[2-(hydroxymethyl)phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)





RN 857070-09-8 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[[[3-(2-methoxyethoxy)-6-methyl-2-pyridinyl]methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857070-10-1 CAPLUS

CN Benzeneethanol, 2-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857070-11-2 CAPLUS

CN 1H-Benzimidazole-6-methanamine, N-(3,5-dimethylphenyl)-1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)





RN 857070-12-3 CAPLUS

CN Benzeneethanol, 2-methyl-6-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)





RN 857070-15-6 CAPLUS

CN 1H-Benzimidazole-6-methanamine, N-(3-methylphenyl)-1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)





RN 857070-18-9 CAPLUS

CN Benzenepropanamide, 2-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)





RN 857070-19-0 CAPLUS

CN Benzonitrile, 3-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857070-20-3 CAPLUS

CN Benzenesulfonamide, 4-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857070-21-4 CAPLUS


CN 1H-Benzimidazole-6-methanamine, N-(3,5-dichlorophenyl)-1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857070-22-5 CAPLUS
 CN 1H-Benzimidazole-6-methanamine, 1-[(6-methyl-2-pyridinyl)methyl]-N-[2-[2-(4-morpholinyl)ethyl]phenyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857070-24-7 CAPLUS
 CN Benzenemethanol, 2-methyl-6-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)



RN 857070-25-8 CAPLUS
 CN Benzenepropanol, 2-[[[1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-5-yl]methyl]amino]-4-methyl- (CA INDEX NAME)





RN 857070-27-0 CAPLUS
 CN Benzenepropanol, 4-methyl-2-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-5-yl]methyl]amino]- (CA INDEX NAME)





RN 857070-29-2 CAPLUS

CN Benzamide, 4-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)



RN 857070-30-5 CAPLUS



CN Benzeneethanol, 3-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)



RN 857070-34-9 CAPLUS



CN Benzamide, 2-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)

NAME)





RN 857070-40-7 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857070-41-8 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)





RN 857070-43-0 CAPLUS

CN Benzenepropanol, 2-[[[1-[(6-bromo-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-5-yl]methyl]amino]-4-methyl- (CA INDEX NAME)





RN 857070-59-8 CAPLUS

CN 1H-Benzimidazole-6-methanamine, N-(3-bromophenyl)-1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857070-60-1 CAPLUS

CN Benzenemethanol, 2-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857070-61-2 CAPLUS

CN Benzenemethanol, 5-methyl-2-[[[1-[(6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)




RN 857071-23-9 CAPLUS

CN Butanamide, 4-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[2-hydroxy-3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]- (CA INDEX NAME)



RN 857083-26-2 CAPLUS


CN 3-Pyridinol, 2-[[[5-[(3,5-dimethylphenyl)amino]methyl]-2-[[3-(tetrahydro-1,4-oxazepin-4(5H)-yl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 857083-27-3 CAPLUS

CN 3-Pyridinol, 2-[[2-[[3-[(2R,6R)-2,6-dimethyl-4-morpholinyl]propyl]amino]-5-[[3,5-dimethylphenyl]amino]methyl]-1H-benzimidazol-1-yl]methyl]-6-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 857083-28-4 CAPLUS

CN 3-Pyridinol, 2-[[2-[[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]propyl]amino]-5-[[3,5-dimethylphenyl]amino]methyl]-1H-benzimidazol-1-yl]methyl]-6-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 857083-29-5 CAPLUS


CN 1H-Benzimidazole-5-methanol, 2-[[3-[(2R,6R)-2,6-dimethyl-4-morpholinyl]propyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 857083-30-8 CAPLUS

CN 1H-Benzimidazole-5-methanol, 2-[[3-[2-(2-hydroxyethyl)-4-morpholinyl]propyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




IT 857083-31-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of morpholine containing benzimidazoles as inhibitors of respiratory syncytial virus replication)

RN 857083-31-9 CAPLUS


CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-thiomorpholinyl)propyl]amino]- (CA INDEX NAME)




IT 857071-96-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of morpholine containing benzimidazoles as inhibitors of
 respiratory syncytial virus replication)
 RN 857071-96-6 CAPLUS
 CN Carbamic acid, [2-[(3,5-dimethylphenyl)[[1-[(3-hydroxy-6-methyl-2-
 pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-
 yl]methyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 857070-63-4P 857070-64-5P 857070-65-6P
 857070-68-9P 857070-83-8P 857070-84-9P
 857070-99-6P 857071-00-2P 857071-01-3P
 857071-02-4P 857071-03-5P 857071-04-6P
 857071-05-7P 857071-08-0P 857071-09-1P
 857071-11-5P 857071-13-7P 857071-15-9P
 857071-17-1P 857071-19-3P 857071-29-5P
 857071-32-0P 857071-34-2P 857071-43-3P
 857071-46-6P 857071-48-8P 857071-58-0P
 857071-60-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of morpholine containing benzimidazoles as inhibitors of
 respiratory syncytial virus replication)
 RN 857070-63-4 CAPLUS
 CN 1H-Benzimidazole-6-carboxylic acid,
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-
 morpholinyl)propyl]amino]-, ethyl ester (CA INDEX NAME)




RN 857070-64-5 CAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid,
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-
 morpholinyl)propyl]amino]-, ethyl ester (CA INDEX NAME)



RN 857070-65-6 CAPLUS
 CN 1H-Benzimidazole-6-carboxaldehyde,
 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-
 morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857070-68-9 CAPLUS
 CN 3-Pyridinol, 2-[[6-(chloromethyl)-2-[[3-(4-morpholinyl)propyl]amino]-1H-
 benzimidazol-1-yl]methyl]-6-methyl-, hydrochloride (1:4) (CA INDEX NAME)




● 4 HCl

RN 857070-83-8 CAPLUS
 CN 3-Pyridinol, 6-methyl-2-[[6-[[[5-methyl-2-[3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-propyn-1-yl]phenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 857070-84-9 CAPLUS
 CN 2-Propenenitrile, 3-[4-[[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-6-yl]methyl]amino]-3,5-dimethylphenyl]- (CA INDEX NAME)




RN 857070-99-6 CAPLUS
 CN 1H-Benzimidazole-6-carboxaldehyde, 2-[[[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]propyl]amino]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 857071-00-2 CAPLUS

CN 4-Morpholineethanol, α -[[[6-(hydroxymethyl)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]- (CA INDEX NAME)




RN 857071-01-3 CAPLUS

CN 4-Morpholineethanol, α -[[[5-(hydroxymethyl)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]- (CA INDEX NAME)




RN 857071-02-4 CAPLUS

CN 1H-Benzimidazole-6-carboxaldehyde, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[2-hydroxy-3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857071-03-5 CAPLUS

CN 1H-Benzimidazole-5-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(tetrahydro-1,4-oxazepin-4(5H)-yl)propyl]amino]- (CA INDEX NAME)




RN 857071-04-6 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(tetrahydro-1,4-oxazepin-4(5H)-yl)propyl]amino]- (CA INDEX NAME)




RN 857071-05-7 CAPLUS

CN 1H-Benzimidazole-6-carboxaldehyde, 1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(tetrahydro-1,4-oxazepin-4(5H)-yl)propyl]amino]- (CA INDEX NAME)




RN 857071-08-0 CAPLUS

CN 2-Morpholineacetic acid, 4-[3-[[6-(hydroxymethyl)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]propyl]-, ethyl ester (CA INDEX NAME)




RN 857071-09-1 CAPLUS

CN 2-Morpholineacetic acid, 4-[3-[[5-(hydroxymethyl)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]propyl]-, ethyl ester (CA INDEX NAME)



RN 857071-11-5 CAPLUS


CN 2-Morpholineacetic acid, 4-[3-[[6-(chloromethyl)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]propyl]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 857071-13-7 CAPLUS

CN 2-Morpholineacetic acid, 4-[3-[[6-[[[(3,5-dimethylphenyl)amino]methyl]-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]propyl]-, ethyl ester (CA INDEX NAME)




RN 857071-15-9 CAPLUS

CN 2-Morpholineacetic acid, 4-[3-[[4,6-dimethyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]amino]propyl]-, ethyl ester (CA INDEX NAME)




RN 857071-17-1 CAPLUS

CN 2-Morpholineacetamide, 4-[3-[[4,6-dimethyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]amino]propyl]- (CA INDEX NAME)



RN 857071-19-3 CAPLUS



CN 4-Morpholineethanol, α -[[[6-(chloromethyl)-1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]-, hydrochloride (1:4) (CA INDEX NAME)



● 4 HCl



RN 857071-29-5 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)





RN 857071-32-0 CAPLUS

CN 1H-Benzimidazole-6-carboxaldehyde, 1-[(3-hydroxy-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



RN 857071-34-2 CAPLUS



CN 3-Pyridinol, 2-[[6-(chloromethyl)-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-, hydrochloride (1:4) (CA INDEX NAME)



● 4 HCl



RN 857071-43-3 CAPLUS

CN 1H-Benzimidazole-6-methanol, 1-[(6-bromo-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)





RN 857071-46-6 CAPLUS

CN 1H-Benzimidazole-6-carboxaldehyde, 1-[(6-bromo-2-pyridinyl)methyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 857071-48-8 CAPLUS
 CN 1H-Benzimidazol-2-amine, 1-[(6-bromo-2-pyridinyl)methyl]-6-(chloromethyl)-
 N-[3-(4-morpholinyl)propyl]-, hydrochloride (1:4) (CA INDEX NAME)




● 4 HCl

RN 857071-58-0 CAPLUS
 CN 1H-Benzimidazole-6-carboxaldehyde,
 1-[(3-methoxy-6-methyl-2-pyridinyl)methyl]-2-[[3-(4-
 morpholinyl)propyl]amino]- (CA INDEX NAME)



RN 857071-60-4 CAPLUS
 CN 1H-Benzimidazol-2-amine, 6-(chloromethyl)-1-[(3-methoxy-6-methyl-2-
 pyridinyl)methyl]-N-[3-(4-morpholinyl)propyl]-, hydrochloride (1:4) (CA
 INDEX NAME)



● 4 HCl

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:564654 CAPLUS

DOCUMENT NUMBER: 143:97359

TITLE: Preparation of amino-benzimidazoles as inhibitors of respiratory syncytial virus replication

INVENTOR(S): Bonfanti, Jean-Francois; Andries, Koenraad Jozef Lodewijk; Janssens, Frans Eduard; Sommen, Francois Maria; Guillemont, Jerome Emile Georges; Lacrampe, Jean Fernand Armand

PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.

SOURCE: PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|----------|
| WO 2005058870 | A1 | 20050630 | WO 2004-EP53617 | 20041220 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004298458 | A1 | 20050630 | AU 2004-298458 | 20041220 |
| CA 2548666 | A1 | 20050630 | CA 2004-2548666 | 20041220 |
| EP 1711485 | A1 | 20061018 | EP 2004-804953 | 20041220 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU | | | | |
| CN 1894236 | A | 20070110 | CN 2004-80037281 | 20041220 |
| BR 2004017808 | A | 20070410 | BR 2004-17808 | 20041220 |
| JP 2007514718 | T | 20070607 | JP 2006-544464 | 20041220 |
| RU 2332414 | C2 | 20080827 | RU 2006-125729 | 20041220 |
| IN 2006DN02972 | A | 20070824 | IN 2006-DN2972 | 20060524 |
| US 20090036466 | A1 | 20090205 | US 2006-596500 | 20060615 |

MX 2006007110
 KR 2006118568
 PRIORITY APPLN. INFO.:


A 20060823
 A 20061123

MX 2006-7110
 KR 2006-713072
 EP 2003-104804
 US 2004-567181P
 WO 2004-EP53617
 20060619
 20060629
 A 20031218
 P 20040430
 W 20041220

OTHER SOURCE(S): CASREACT 143:97359; MARPAT 143:97359
 GI



I



II

AB The title compds. [I; Q = Ar2, cycloalkyl or (un)substituted alkyl; G = a direct bond or (un)substituted alkanediyl; R1 = Ar1 or a monocyclic or bicyclic heterocycle; one of R2a and R3a = alkyl and the other one of R2a and R3a = H; in case R2a is different from hydrogen then R2b = H or alkyl, and R3b = H; in case R3a is different from hydrogen then R3b = H or alkyl, and R2b = H; or R2a, R2b, R3a and R3b all = H; R5 = H, alkyl; Ar1, Ar2 = (un)substituted Ph; and their prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochem. isomeric forms] having inhibitory activity on the replication of the respiratory syncytial virus, were prepared E.g., a multi-step synthesis of II, starting from (3-benzoyloxy-6-methylpyridin-2-yl)methanol, was given. The exemplified compds. I were tested for activity against RSV (data given). The invention further concerns preparation of compds. I and compns. comprising them, as well as their use as a medicine.


IT 856895-07-3P 856895-14-2P 856895-16-4P
 856895-18-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of amino-benzimidazoles as inhibitors of respiratory syncytial virus replication)


RN 856895-07-3 CAPLUS

CN β -Alanine, N-[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4,6-dimethyl-1H-benzimidazol-2-yl]-, ethyl ester (CA INDEX NAME)




RN 856895-14-2 CAPLUS

CN Benzonitrile, 4-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4,6-dimethyl-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 856895-16-4 CAPLUS

CN 2-Pyrrolidinone, 1-[3-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4,6-dimethyl-1H-benzimidazol-2-yl]amino]propyl]- (CA INDEX NAME)



RN 856895-18-6 CAPLUS

CN 3-Pyridinol, 2-[[2-[[4-(2-aminoethyl)phenyl]amino]-5,7-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



IT 856894-96-7P 856894-97-8P 856894-98-9P
 856894-99-0P 856895-00-6P 856895-01-7P
 856895-02-8P 856895-03-9P 856895-04-0P
 856895-05-1P 856895-06-2P 856895-08-4P
 856895-09-5P 856895-10-8P 856895-11-9P
 856895-12-0P 856895-13-1P 856895-15-3P
 856895-17-5P 856895-19-7P 856895-20-0P
 856895-21-1P 856895-22-2P 856895-23-3P
 856895-24-4P 856895-25-5P 856895-26-6P
 856895-27-7P 856895-28-8P 856895-29-9P
 856895-30-2P 856895-31-3P 856895-32-4P
 856895-33-5P 856895-34-6P 856895-35-7P

856895-36-8P 856895-37-9P 856895-38-0P


856895-44-8P 856895-45-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino-benzimidazoles as inhibitors of respiratory syncytial virus replication)


RN 856894-96-7 CAPLUS

CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[[3-(1-piperidiny)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856894-97-8 CAPLUS

CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[[3-(1-pyrrolidiny)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856894-98-9 CAPLUS

CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856894-99-0 CAPLUS

CN 1,2-Propanediol, 3-[[1-[(3-hydroxy-6-methyl-2-pyridiny)methyl]-4,6-dimethyl-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 856895-00-6 CAPLUS

CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[[2-(1-methyl-2-pyrrolidiny)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-01-7 CAPLUS

CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[[2-(1-piperidiny)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-02-8 CAPLUS

CN 3-Pyridinol, 2-[[2-[(3-hydroxypropyl)amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-03-9 CAPLUS


CN Propanamide, 3-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4,6-dimethyl-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 856895-04-0 CAPLUS
 CN 3-Pyridinol, 2-[[2-[[4-(aminomethyl)phenyl]amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-05-1 CAPLUS
 CN 3-Pyridinol, 2-[[2-[[3-(1H-imidazol-1-yl)propyl]amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-06-2 CAPLUS
 CN 3-Pyridinol, 2-[[2-[[2-(1H-imidazol-5-yl)ethyl]amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-08-4 CAPLUS
 CN 3-Pyridinol, 2-[[2-[[4-(2-aminoethyl)phenyl]amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-09-5 CAPLUS
 CN 3-Pyridinol, 2-[[2-[(4-aminophenyl)amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 856895-10-8 CAPLUS
 CN 3-Pyridinol, 2-[[4,6-dimethyl-2-[(2-pyridinylmethyl)amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-11-9 CAPLUS
 CN 3-Pyridinol, 2-[[2-[(3-methoxypropyl)amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-12-0 CAPLUS

CN 3-Pyridinol, 2-[[2-(cyclohexylamino)-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-13-1 CAPLUS

3-Pyridinol, 2-[[4,6-dimethyl-2-[(2-phenylethyl)amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-15-3 CAPLUS

CN 3-Pyridinol, 2-[[[2-[[[2-(2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-17-5 CAPLUS


CN Benzenesulfonamide, 4-[2-[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4,6-dimethyl-1H-benzimidazol-2-yl]amino]ethyl)- (CA INDEX NAME)




RN 856895-19-7 CAPLUS
 CN 3-Pyridinol, 2-[[2-[(cyclohexylmethyl)amino]-5,7-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 856895-20-0 CAPLUS
 CN 3-Pyridinol, 6-methyl-2-[[2-[[3-(1-piperidinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 856895-21-1 CAPLUS
 CN 3-Pyridinol, 6-methyl-2-[[2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 856895-22-2 CAPLUS

CN 1,2-Propanediol, 3-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 856895-23-3 CAPLUS

CN 3-Pyridinol, 6-methyl-2-[[2-[[3-(1-pyrrolidinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 856895-24-4 CAPLUS

CN 3-Pyridinol, 2-[[2-[[2-(4-methoxyphenyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-25-5 CAPLUS

CN 3-Pyridinol, 2-[[2-[[[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-26-6 CAPLUS

CN 3-Pyridinol, 2-[[2-[(5-hydroxypentyl)amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-27-7 CAPLUS

CN 3-Pyridinol, 2-[[2-[(3-hydroxypropyl)amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-28-8 CAPLUS

CN 3-Pyridinol, 2-[[2-[(6-hydroxyhexyl)amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-29-9 CAPLUS

CN 3-Pyridinol, 2-[[2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-30-2 CAPLUS

CN 2-Pyrrolidinone, 1-[3-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]propyl]- (CA INDEX NAME)




RN 856895-31-3 CAPLUS

CN 3-Pyridinol, 6-methyl-2-[[2-[[3-(methylthio)propyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 856895-32-4 CAPLUS

CN Butanoic acid, 4-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]-, ethyl ester (CA INDEX NAME)




RN 856895-33-5 CAPLUS


CN Butanamide, 4-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 856895-34-6 CAPLUS
 CN 3-Pyridinol, 2-[[2-[[2-(1H-indol-3-yl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 856895-35-7 CAPLUS
 CN 3-Pyridinol, 6-methyl-2-[[2-[[2-(2-pyridinyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]- (CA INDEX NAME)




RN 856895-36-8 CAPLUS
 CN 3-Pyridinol, 2-[[2-[[2-(3-fluorophenyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-37-9 CAPLUS

CN 3-Pyridinol, 2-[[2-[[2-(4-fluorophenyl)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




RN 856895-38-0 CAPLUS

CN 3-Pyridinol, 2-[[2-[[2-(2-hydroxyethoxy)ethyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)



RN 856895-44-8 CAPLUS

CN 3-Pyridinol, 2-[[2-[[4-(2-aminoethyl)phenyl]amino]-4,6-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl-, hydrochloride (1:4) (CA INDEX NAME)



● 4 HCl


RN 856895-45-9 CAPLUS

CN 3-Pyridinol, 2-[[2-[[4-(2-aminoethyl)phenyl]amino]-5,7-dimethyl-1H-benzimidazol-1-yl]methyl]-6-methyl-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 856895-18-6


CMF C24 H27 N5 O



CM 2

CRN 64-19-7

CMF C2 H4 O2




IT 856895-40-4P 856895-41-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of amino-benzimidazoles as inhibitors of respiratory syncytial virus replication)


RN 856895-40-4 CAPLUS

CN 1H-Benzimidazol-2-amine, 4,6-dimethyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)



RN 856895-41-5 CAPLUS

CN 1H-Benzimidazol-2-amine, N-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,6-dimethyl-1-[[6-methyl-3-(phenylmethoxy)-2-pyridinyl]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:117213 CAPLUS

DOCUMENT NUMBER: 140:163868

TITLE: Preparation of acylaminoheteroarenes as upregulators of endothelial nitric oxide synthase (eNOS).

INVENTOR(S): Strobel, Hartmut; Wohlfart, Paulus; Below, Peter

PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany

SOURCE: Eur. Pat. Appl., 40 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| EP 1388341 | A1 | 20040211 | EP 2002-17585 | 20020807 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| CA 2494298 | A1 | 20040219 | CA 2003-2494298 | 20030724 |
| WO 2004014369 | A1 | 20040219 | WO 2003-EP8102 | 20030724 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2003260325 | A1 | 20040225 | AU 2003-260325 | 20030724 |
| EP 1534275 | A1 | 20050601 | EP 2003-784054 | 20030724 |
| EP 1534275 | B1 | 20080312 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003013294 | A | 20050712 | BR 2003-13294 | 20030724 |
| JP 2005538123 | T | 20051215 | JP 2004-526764 | 20030724 |
| AT 388702 | T | 20080315 | AT 2003-784054 | 20030724 |
| US 20040110808 | A1 | 20040610 | US 2003-634979 | 20030805 |
| US 7338956 | B2 | 20080304 | | |
| MX 2005000697 | A | 20050408 | MX 2005-697 | 20050117 |
| PRIORITY APPLN. INFO.: | | | EP 2002-17585 | A 20020807 |

US 2002-432314P


P 20021210

WO 2003-EP8102

W 20030724

OTHER SOURCE(S):
GI

MARPAT 140:163868



AB Title compds. [I; R1, R4 = H, (substituted) alkyl, alkenyl, alkynyl, Ph, heteroaryl; R2, R3 = H, OH, halo, cyano, alkoxy, PhO, (substituted) alkyl, PhCONH, etc.; R5 = (substituted) aryl, heteroaryl; X = NR30, S, O, CH:CH, N:CH; R30 = H, (substituted) alkyl, alkenyl, alkynyl], were prepared. Thus, title compound I (R1-R4 = H; R5 = 4-FC6H4; X = NH) (preparation outlined) activated eNOS transcription with EC50 = 0.028 μ M.


IT 656250-85-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of acylaminoheteroarenes as upregulators of endothelial nitric oxide synthase)

RN 656250-85-0 CAPLUS

CN Benzamide, 4-fluoro-N-[1-[2-(2-pyridinyl)ethyl]-5-(trifluoromethyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



REFERENCE COUNT:

19

THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:363331 CAPLUS

DOCUMENT NUMBER: 137:93712

TITLE: Rapid Microwave-Assisted Liquid-Phase Combinatorial Synthesis of 2-(Arylamino)benzimidazoles

AUTHOR(S): Bendale, Pravin M.; Sun, Chung-Ming

CORPORATE SOURCE: Department of Chemistry, National Dong Hwa University, Hualien, 974, Taiwan

SOURCE: Journal of Combinatorial Chemistry (2002), 4(4), 359-361

CODEN: JCCHFF; ISSN: 1520-4766

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:93712


AB An efficient, facile, and practical liquid-phase combinatorial synthesis of

benzimidazoles under microwave irradiation is described. In the first step, polymer-bound activated aryl fluoride was condensed with selective primary amines via an ipso-fluoro displacement reaction. Reduction of the polymer-bound nitro group followed by cyclization with isothiocyanates afforded immobilized benzimidazoles. The desired products were obtained in high yield with high purity after detaching from the soluble matrix. All reactions involved (S_NAr reaction, reduction, cyclization, and support cleavage) were performed completely within a few minutes under microwave irradiation. The coupling of microwave technol. with liquid-phase combinatorial synthesis constitutes a novel and particularly attractive avenue for the rapid generation of structurally diverse libraries.

IT 442129-64-8P 442129-68-2P
 RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
 (rapid microwave-assisted liquid-phase combinatorial synthesis of 2-(arylamino)benzimidazoles)
 RN 442129-64-8 CAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid,
 2-(phenylamino)-1-[2-(2-pyridinyl)ethyl]-, methyl ester (CA INDEX NAME)



RN 442129-68-2 CAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid,
 2-[(4-fluorophenyl)amino]-1-[2-(2-pyridinyl)ethyl]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2002:97991 CAPLUS
 DOCUMENT NUMBER: 137:93711
 TITLE: Soluble polymer-supported synthesis of 2-(arylamino)benzimidazoles
 AUTHOR(S): Wu, Cheng-Yi; Sun, Chung-Ming
 CORPORATE SOURCE: Department of Chemistry, National Dong Hwa University, Shou-Feng, Hualien, 974, Taiwan
 SOURCE: Tetrahedron Letters (2002), 43(8), 1529-1533
 CODEN: TELEAY; ISSN: 0040-4039
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:93711


AB A novel liquid-phase method for the construction of biol. important benzimidazoles has been developed. A library of N-substituted 2-aminobenzimidazoles was readily assembled utilizing SNAr reactions, reduction of the nitro group, and a one-pot cyclization with isothiocyanate as the key step in the synthesis. The crude benzimidazoles were obtained in 80-99% yields with 78-95% HPLC purity.

IT 442129-64-8P 442129-68-2P 442129-73-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(soluble polymer-supported synthesis of (arylamino)benzimidazoles)


RN 442129-64-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid,
2-(phenylamino)-1-[2-(2-pyridinyl)ethyl]-, methyl ester (CA INDEX NAME)




RN 442129-68-2 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid,
2-[(4-fluorophenyl)amino]-1-[2-(2-pyridinyl)ethyl]-, methyl ester (CA INDEX NAME)



RN 442129-73-9 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid,
2-[(3-methylphenyl)amino]-1-[2-(2-pyridinyl)ethyl]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:12444 CAPLUS

DOCUMENT NUMBER: 134:86248

TITLE: Preparation of benzimidazoles as respiratory syncytial virus replication inhibitors.

INVENTOR(S): Janssens, Frans Eduard; Meersman, Kathleen Petrus Marie-Jose; Sommen, Francois Maria; Guillemont, Jerome Emile Georges; Lacrampe, Jean Fernand Armand; Andries, Koenraad Jozef Lodewijk Marcel

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|----------|
| WO 2001000611 | A1 | 20010104 | WO 2000-EP5676 | 20000620 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2376781 | A1 | 20010104 | CA 2000-2376781 | 20000620 |
| BR 2000012054 | A | 20020319 | BR 2000-12054 | 20000620 |
| EP 1196408 | A1 | 20020417 | EP 2000-943841 | 20000620 |
| EP 1196408 | B1 | 20040915 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| TR 200103804 | T2 | 20020521 | TR 2001-3804 | 20000620 |
| HU 2002001723 | A2 | 20021128 | HU 2002-1723 | 20000620 |
| HU 2002001723 | A3 | 20040428 | | |
| JP 2003503401 | T | 20030128 | JP 2001-507020 | 20000620 |
| EE 200100692 | A | 20030217 | EE 2001-692 | 20000620 |
| EE 4590 | B1 | 20060215 | | |
| NZ 515418 | A | 20031128 | NZ 2000-515418 | 20000620 |
| EP 1418175 | A1 | 20040512 | EP 2004-100543 | 20000620 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI, MK, CY, AL | | | | |
| AT 276244 | T | 20041015 | AT 2000-943841 | 20000620 |
| AU 779516 | B2 | 20050127 | AU 2000-58167 | 20000620 |
| PT 1196408 | T | 20050131 | PT 2000-943841 | 20000620 |
| ES 2228559 | T3 | 20050416 | ES 2000-943841 | 20000620 |
| CN 1239496 | C | 20060201 | CN 2000-809619 | 20000620 |
| AP 1552 | A | 20060228 | AP 2002-2397 | 20000620 |
| W: GM, GH, KE, LS, MW, MZ, SL, SD, SZ, TZ, UG, ZM, ZW | | | | |
| SG 122814 | A1 | 20060629 | SG 2004-362 | 20000620 |
| TR 200600172 | T1 | 20070122 | TR 2006-172 | 20000620 |
| PL 198021 | B1 | 20080530 | PL 2000-362890 | 20000620 |
| TW 248932 | B | 20060211 | TW 2000-89112477 | 20000626 |
| EG 24026 | A | 20080326 | EG 2000-833 | 20000627 |
| IN 2001MN01539 | A | 20050304 | IN 2001-MN1539 | 20011206 |
| MX 2002000112 | A | 20020702 | MX 2002-112 | 20011219 |
| HR 2001000933 | A1 | 20030630 | HR 2001-933 | 20011219 |
| ZA 2001010478 | A | 20030320 | ZA 2001-10478 | 20011220 |
| NO 2001006368 | A | 20020228 | NO 2001-6368 | 20011227 |
| NO 324036 | B1 | 20070730 | | |
| US 6924287 | B1 | 20050802 | US 2001-30202 | 20011227 |
| BG 106287 | A | 20021031 | BG 2002-106287 | 20020108 |

| | | | | |
|----------------|----|----------|----------------|----------|
| BG 65372 | B1 | 20080430 | | |
| HK 1046141 | A1 | 20060922 | HK 2002-107761 | 20021025 |
| US 20050234047 | A1 | 20051020 | US 2005-144103 | 20050603 |
| US 7173054 | B2 | 20070206 | | |
| US 20050239771 | A1 | 20051027 | US 2005-144126 | 20050603 |
| US 7173034 | B2 | 20070206 | | |
| US 20060154913 | A1 | 20060713 | US 2006-332557 | 20060112 |
| US 7361657 | B2 | 20080422 | | |
| US 20070021410 | A1 | 20070125 | US 2006-519719 | 20060911 |
| US 7390811 | B2 | 20080624 | | |

PRIORITY APPLN. INFO.:

| | | |
|----------------|----|----------|
| EP 1999-202087 | A | 19990628 |
| EP 2000-200452 | A | 20000211 |
| EP 2000-943841 | A3 | 20000620 |
| WO 2000-EP5676 | W | 20000620 |
| US 2001-30202 | A3 | 20011227 |
| US 2005-144103 | A3 | 20050603 |

OTHER SOURCE(S): MARPAT 134:86248
GI



AB Use of title compds. [I; a1:a2a3:a4 = (substituted) CH:CHCH:CH, N:CHCH:CH, CH:N:CH:CH, CH:CHN:CH, CH:CHCH:N; Q = R2R4NAX1, R2R4NCOAX1, specified (heterocyclic) ring, etc.; A = alkylene; R2 = H, CHO, alkylcarbonyl, pyrrolidinyl, piperidinyl, homopiperidinyl, aminocycloalkyl, etc.; R4 = H, alkyl, aralkyl; G = bond, alkanediyl; R1 = (substituted) piperidinyl, piperazinyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, etc.] for treatment of viral infection is claimed. Thus, 1,1-dimethylethyl 4-[[1-[[3,5-dihydro-3,3-dimethyl-9-(phenylmethoxy)-1H-1,3-dioxepino[5,6-c]pyridin-2-yl]methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylate was refluxed 6 h in 10N HCl to give 4-[[1-[[3,5-dihydro-3,3-dimethyl-9-(phenylmethoxy)-1H-1,3-dioxepino[5,6-c]pyridin-2-yl]methyl]-1H-benzimidazol-2-yl]amino]piperidine. Tested I inhibited respiratory syncytial virus replication with IC50 = 0.00013-2.5119 μ M.


IT 1100824-97-2 1100824-98-3 1100824-99-4
1100825-01-1 1100825-48-6

RL: PRPH (Prophetic)

(Preparation of benzimidazoles as respiratory syncytial virus replication inhibitors.)


RN 1100824-97-2 CAPLUS

CN 1,3-Propanediamine, N1-[1-[(6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]-, hydrochloride (1:5) (CA INDEX NAME)



●5 HCl


RN 1100824-98-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



●4 HCl

● H₂O


RN 1100824-99-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



●4 HCl

● H₂O


RN 1100825-01-1 CAPLUS
 CN 1,3-Propanediamine, N1-[1-[(6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]-2-(phenylmethoxy)-, hydrochloride, hydrate (1:3:1) (CA INDEX NAME)



●3 HCl


● H₂O

RN 1100825-48-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

CC(=O)NCC[C@H]1CCCC[C@@H]1NC(=N)N2C(=N)C3=CC=CC=C3N2Cc4c[nH]c5ccccc45CC(=O)NCCN[C@H]1CCCC[C@@H]1NC2=NC(=C3C=CC=CC=C3N=C2)CN(C4=CC=CC=C4)C5=CC=CC=C5

| | | |
|----|--|--------|
| RN | 317846-37-0 | CAPLUS |
| CN | 3-Pyridinol, 2-[[2-[(3-amino-2-hydroxypropyl)amino]-1H-benzimidazol-1- | |


yl)methyl]-6-methyl- (CA INDEX NAME)



RN 317846-94-9 CAPLUS

CN 1,4-Cyclohexanediamine, N1-(2-aminoethyl)-N4-[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]-, hydrochloride (1:4), trans- (CA INDEX NAME)


Relative stereochemistry.



● 4 HCl

RN 317846-95-0 CAPLUS

CN 1H-Benzimidazol-2-amine, N-[[1-(2-aminoethyl)-3-piperidinyl]methyl]-1-(2-pyridinylmethyl)-, hydrochloride (1:4) (CA INDEX NAME)



● 4 HCl


IT 317847-82-8

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of benzimidazoles as respiratory syncytial virus replication inhibitors)

RN 317847-82-8 CAPLUS

CN 3-Pyridinol, 2-[[2-[[3-[bis(phenylmethyl)amino]-2-(phenylmethoxy)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (CA INDEX NAME)




IT 317847-49-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of benzimidazoles as respiratory syncytial virus replication
 inhibitors)
 RN 317847-49-7 CAPLUS
 CN Cyclohexanone, 4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]- (CA
 INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1995:752271 CAPLUS
 DOCUMENT NUMBER: 123:339888
 ORIGINAL REFERENCE NO.: 123:61003a,61006a
 TITLE: N-(1-Phenyl-2-benzimidazolyl)-N'-phenylurea
 derivatives as potent inhibitors of
 acyl-CoA:cholesterol acyltransferase (ACAT)
 AUTHOR(S): Kumazawa, Toshiaki; Harakawa, Hiroyuki; Fukui, Hiromi;
 Shirakura, Shiro; Ohishi, Eiko; Yamada, Koji
 CORPORATE SOURCE: Pharm. Res. Lab., Kyowa Hakko Kogyo Co., Ltd.,
 Shizuoka, 411, Japan
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1995),
 5(16), 1829-32
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB N-(1-phenyl-2-benzimidazolyl)-N'-phenylurea derivs., e.g., I, were prepared as ACAT inhibitors. These compds. showed potent ACAT inhibitory activity in vitro (liver microsomes from cholesterol-fed rabbits) and hypocholesterolemic activity in vivo (cholesterol-fed golden hamsters).

IT 170752-07-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (phenylbenzimidazolyl)phenylureas as potent inhibitors of ACAT)


RN 170752-07-5 CAPLUS

CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[1-(3-chloro-2-pyridinyl)-1H-benzimidazol-2-yl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 170752-06-4


CMF C25 H26 Cl N5 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



L6 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:709095 CAPLUS

DOCUMENT NUMBER: 123:218414

ORIGINAL REFERENCE NO.: 123:38595a,38598a

TITLE: Imidazoles and antiarteriosclerotics containing the imidazoles

INVENTOR(S): Kumazawa, Toshiaki; Harakawa, Hiroyuki; Fukui, Hiromi; Shirokura, Shiro; Ooishi, Eiko; Yamada, Koji

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Kk, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--------|------------|-----------------|----------|
| JP 07133224 | A | 19950523 | JP 1993-280961 | 19931110 |
| PRIORITY APPLN. INFO.: | | | JP 1993-280961 | 19931110 |
| OTHER SOURCE(S): | MARPAT | 123:218414 | | |
| GI | | | | |




I

AB Antiarteriosclerotics contain imidazoles I [X, Y = CH, N; Z = single bond, CH₂; R₁, R₂, R₃ = H, halo, lower alkyl, OH, lower alkoxy, carboxy, lower alkoxy-carbonyl, NH₂, mono- or di-lower alkyl-substituted amino, carbamoyl, mono- or di-lower alkyl-substituted carbamoyl, CF₃; R₄, R₅, R₆ = H, halo, lower alkyl, lower alkoxy; R₇ = H, lower alkyl, lower alkyl-(un)substituted cycloalkyl] or their pharmacol. acceptable salts as active ingredients. N-[1-(2-chlorophenyl)-2-benzimidazolyl]-N'-(2,6-diisopropylphenyl)urea (II) (2.3 g) was prepared by treatment of 1.5 g 2-amino-1-(2-chlorophenyl)benzimidazole and 1.46 mL 2,6-diisopropylphenyl isocyanate. II (at 10⁻⁷M) inhibited acyl CoA:cholesterol acyltransferase by 85%. II showed min. LD of >100 mg/kg i.p. in mice. A formulation example of tablets is given.

IT 168120-34-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (antiarteriosclerotics containing imidazoles)

RN 168120-34-1 CAPLUS

CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[1-(4-methyl-2-pyridinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



=> fil stnguide
 COST IN U.S. DOLLARS

SINCE FILE

TOTAL

| | | |
|--|------------|---------|
| FULL ESTIMATED COST | ENTRY | SESSION |
| | 94.48 | 281.54 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| CA SUBSCRIBER PRICE | -13.12 | -13.12 |

FILE 'STNGUIDE' ENTERED AT 09:11:55 ON 12 FEB 2009
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Feb 6, 2009 (20090206/UP).

=>

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

| | | |
|--|------------|---------|
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 2.03 | 283.57 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| CA SUBSCRIBER PRICE | 0.00 | -13.12 |

STN INTERNATIONAL LOGOFF AT 09:29:18 ON 12 FEB 2009